



UNIVERSITÀ
di VERONA

Dipartimento
di **MEDICINA**

IL DIRETTORE
Prof. Oliviero Olivieri

Verona, 15.11.2018

Alla cortese attenzione della
Prof.ssa Gabriela Constantin,
Decano del Consiglio della Scuola di Dottorato in Scienze della vita e della salute
e dell'Ufficio Dottorati di Ricerca dell'Ateneo di Verona

Cara Gabriela,

con questa mia intendo presentare la mia candidatura per la nomina a Direttore della Scuola di Dottorato in Scienze della vita e della salute.

Allego, come richiesto, il mio CV rimanendo a disposizione per ogni eventuale richiesta, e porgo a te e allo Staff degli Uffici un saluto cordiale

Vincenzo Bronte

A handwritten signature in blue ink, appearing to read "Vincenzo Bronte".

Curriculum vitae et studiorum

Vincenzo Bronte, M.D.

- Place of birth: Gela (Caltanissetta), Italy.
- Date of birth: 24-08-1963.
- Phone: 0039-045-8124007 (w); fax: 0039-045-8126455 (w); e-mail: vincenzo.bronte@univr.it.
- Citizenship: Italian.
- Married with 2 children.

EDUCATION

- 07.18.1988: Medical Degree (M.D.) summa cum laude, University of Padova.
- 12.21.1992: Specialization (70/70) in Allergy and Clinical Immunology, University of Padova.

PROFESSIONAL EXPERIENCE

- November - December, 1989: visiting fellow at the Roche laboratories, Basel, Switzerland.
- 1988-1989: Fellowship from Fidia Pharmaceuticals - research project developed in the Oncology Institute in the University of Padua.
- 1990 -1992: Post-doctoral fellowship from "Italian Association for Cancer Research".
- February 1994 - September 1996: Exchange scientist at the Surgery Branch of the National Cancer Institute, National Institute of Health, Bethesda.

AWARDS AND HONORS

- April 2007: Winner of the International Prize "Francesco De Luca" for scientific Oncology career awarded by the Accademia Nazionale dei Lincei, Rome, Italy.
- July 2008: Winner of the prize "Timone d'argento" awarded by Lion's Club of Gela, for distinguished Sicilians in the field of art, literature, economy, sport, and science.
- November 2008: Winner of the Prize "Guido Venosta" for oncology researchers awarded by the Italian Foundation for Cancer Research (FIRC).

POSITION HELD

From January 2011, Full Professor of Immunology and Head of the Immunology Section in the Department of Pathology and Diagnostics, Medicine Faculty until 2015, from 2015 to date in the Department of Medicine, Verona University.

1992 - to December 2010, Staff scientist - clinical associate at the Istituto Oncologico Veneto (IRCCS), Via Gattamelata 64, 35128 Padova, Italy; Contract professor of Immunology and Pathology at Medicine Faculty in Padova University.

1997 - 2010, Head of the HLA typing laboratory and Oncogenomic Unit at Istituto Oncologico Veneto.

2007- 2014, Group leader at the Venetian Institute for Molecular Medicine, Via G. Orus 2, 35129, Padova, Italy.

EDITORIAL BOARD

2001 - Current Gene Therapy
2003 - Journal of Translational Medicine
2009 - Consulting Editor of Journal of Clinical Investigation
2010 - Journal of Immunology
2011 - Frontiers in Tumor Immunity
2013 – Journal of Immunology - Section Editor
2013 – Cancer Immunology Research
2014 – Frontiers in Oncology
2017 - Cell Stress

GUEST EDITOR

2018 – Seminars in Immunology; He coordinated the edition titled “The mesenchymal and myeloid regulation of immunity” Volume 35, pages 1-80, February 2018

SOCIETY BOARD

2008 – Board of Scientific Advisors of the Accademia Nazionale di Medicina.
2009 – Board of Directors of the Cancer Italian Society (SIC).
2012 – Board of Advisory Scientific Committee of “Corso Avanzato di Citometria a Flusso – Applicazioni in Oncologia e Immunologia”, Verona.
2013 – Board of *Advisory Scientific Committee of 15th International Congress of Immunology*, Milano.
2015 – Member of Cancer Immunotherapy Fellowship Awards and Immune Biomarkers Task Force of the international Society for Immunotherapy of Cancer (SITC).
2016 – Board of International Scientific Organizing Committee of Regulatory Myeloid Suppressor Cells Conference, 16-19 June, Philadelphia.
2016 – Board of Local Scientific Committee of 58th Annual Meeting of the Italian Cancer Society (SIC): Revolutionary Road. Accelerating conversion of cancer biology into personalized clinical oncology, 5-8 September, Verona.
2016 - Elected member of European Academy for Tumor Immunology (EATI).
2017 - Member of the Advisory Committee of Fondazione Pisana per la Scienza (FPS).
2018 – Board of International Scientific Organizing Committee for the 32nd annual EMDS (European Macrophage and Dendritic Cell Society), The cross-road between macrophages and dendritic cells: from immunometabolism to single cell fate, 27-29 September 2018, Verona, Italy.
2018 – Board of the Scientific council of the Network Italiano per la BioTerapia dei Tumori (NIBIT).

ID FUNDING

- Italy-US program for the therapy of cancer. Ministero della Sanità, Istituto Superiore di Sanità, accordo di collaborazione scientifica n. T00.A17. Project "Novel therapeutic approaches to overcome dysfunction of the immune responses caused by myeloid suppressor cells during neoplastic growth". ITL 900000000 (about € 45.000)/year for 3 years (2001-2003).
- University of Padova. Project: "Differential gene expression in myeloid cells regulating the function of T lymphocytes". ITL 120000000 (about € 60.000) for 2 years (2002-2003).
- National coordinator of the project FIRB-MIUR "Genomic and functional analysis of accessory cells with regulatory activity on immune responses" (code: RBAU01935A). € 200.000 for 3 years (2004-2006).
- Istituto Superiore Sanità (contract 530/F-A3). Project: "Use of novel drugs affecting L-arginine metabolism in myeloid suppressor cells as adjuvant of adoptive cancer immunotherapy". € 50.000 for 2 years (2004-2005).
- Associazione Italiana per la Ricerca sul Cancro (AIRC). Project: "MicroRNA in haematological cancers: a high-throughput approach based on tissue-specific microRNA libraries". € 600.000 for 3 years (2006-2008). Codice progetto IG 4175
- Fondazione Italiana Sclerosi Multipla ONLUS (FISM). Project: "Myeloid suppressor cells as a novel regulatory population to restrain autoimmune aggression in multiple sclerosis". € 68.000 for 3 years (2006-2008).
- U.S. Department of Defence (ARMY). Project: "Defining novel molecules to rescue immunity against prostate cancer: molecular and biological bases for new therapies". Coordinator: Dr. Antonella Viola. \$ 432.000 for 3 years (2006-2008).
- Italy-Quebec program for scientific cooperation and technology development. Project: "Metabolome and transcriptome analysis of tumor microenvironment: from pathogenetic mechanisms to marker discovery". The program cover personnel travel expenses between Istituto Oncologico Veneto in Padova and Ecole Polytechnique in Montreal (2006-2008).
- Istituto Superiore Sanità per Alleanza Contro il Cancro, programma per la ricerca oncologica. "Rete solidale e collaborazioni internazionali" (DM del 21 luglio 2006, Art. 3, ISS per ACC). Project: "Development of new drugs restoring antitumor immune response by altering tumor microenvironment". € 1.200.000 for 2 years (2007-2009).
- Italy-US program, Istituto Superiore di Sanità, Contract 527/A/3A/1. Project: "Micro-RNA in haematological cancers: a high-throughput approach based on tissue-specific microRNA libraries". € 250.000 for 16 months (2007-2008).
- Association for International Cancer Research, United Kingdom. Project: "Evaluating the role of arginase 1 in tumor development and tumor-induced tolerance". £ 138.000 for 3 years (2008-2010).
- Programma Integrato per la Ricerca Oncologica, Ministero della Salute: "n. RO Strategici 8/07. Project "Microambiente tumorale: ruolo nella progressione neoplastica ed effetti sulle difese dell'ospite. Identificazione di nuovi bersagli per lo sviluppo di terapie innovative. € 145.000 for 2 years (2008-2011).
- Ricerca Oncologica 2006, Progetto ex art 12 Ministero, Prot. N 381143/50.00.034. Project: "Identification of novel molecular targets in pancreatic cancer by analysis of tumor-stroma interaction". € 148.000 for 2 years (2009-2010).
- Fondazione della Cassa di Risparmio di Padova e Rovigo. Progetti di Eccellenza, Bando 2007/2008. Project: Myeloid-derived suppressor cells in chronic inflammation and cancer, € 420.000 for 3 years (2008-2010).

- University of Padova. Project: Role of arginase 1 in tumor promotion and induction of tumor-associated immune dysfunctions. € 71.000 for 2 years (2009-2010).
- EU grant, Euronanomed call. Project: Lymphonanocarriers for the treatment of metastatic cancer, € 200.000 for 3 years (2010-2012).
- Associazione Italiana per la Ricerca sul Cancro (AIRC). Project: "AREA 2: An integrated approach to chronic lymphoproliferative disorders: B-CLL and virus-related neoplasia". € 400.000 for 3 years (2009-2012). Codice progetto Multi Unit Regional – 6599.
- Associazione Italiana per la Ricerca sul Cancro (AIRC). Project: "Innovative tools for early diagnosis and risk assessment of pancreatic cancer ". € 961.636,50 for five years (2011-2017). Codice progetto – Multi Unit Airc 5x1000 – 12182.
- Associazione Italiana per la Ricerca sul Cancro (AIRC). Project: "Reprogramming tumor environment to increase the effectiveness of cancer immunotherapy". € 390.000 for 3 years (2011-2014). Codice progetto IG 10400.
- Fondazione della Cassa di Risparmio di Padova e Rovigo . Project: "Immunotherapy of prostate cancer: promises and limitations". 1.500.000 for 3 years (2012-2014).
- Ministero dell'Istruzione, dell'Università e della Ricerca. Project: "Rna e nanotecnologie del controllo dell'immunosoppressione neoplastica sostenuta dal catabolismo degli amino acidi (RNA and nanotechnology for the control of cancer-dependent immunosuppression by amino acid catabolism)". € 460.400 for three years (2012-2015). Progetto FIRB codice CUP: B31J11000420001.
- EU grant, 7th Framework Programme. Project: "New Oral Nanomedicines: transporting therapeutic macromolecules across the intestinal barrier (acronym: Trans-int)". € 301.400 for five years (2012-2017).
- Associazione Italiana per la Ricerca sul Cancro (AIRC). Project: "Molecular control of the metastatic process by adaptive and innate immunity". € 530.000 for 3 years (2014-2017). Codice progetto IG 14103.
- Associazione Italiana per la Ricerca sul Cancro (AIRC). Project: "AREA 2: An integrated approach to chronic lymphoproliferative disorders: B-CLL and virus-related neoplasia". € 124.700 for 2 years (2013-2015) - Codice progetto Multi Unit Regional – 6599.
- Ministero della Salute. Project: "Investigation of the role of extracellular ATP and the P2X7 receptor in the modulation of immunosuppression within tumour microenvironment" – Progetto Finalizzata codice CUP E35G14000190001. € 230.000 for 3 years (2014-2017).
- Associazione Italiana per la Ricerca sul Cancro (AIRC). Project: "Exosome-driven antiviral response in the metastatic dissemination of pancreatic cancer". € 634.000 for 3 years (2017-2019). Codice progetto IG 18603.
- Cancer Research Institute Clinic and Laboratory Integration Program (CLIP) Grant. Project: "Neutralizing human arginase to enhance cancer immunotherapy". \$192,000 for 2 years (2017-2019).
- TUSK Therapeutics Limited provided a contribution of €49.600 in relation to the research conducted by Prof. Bronte described in the Material Transfer Agreement dated June 12th, 2016.
- Fondazione Cariverona. Project: "Analisi e caratterizzazione delle cellule mieloidi in neoplasie solide ed ematologiche" € 360.000,00 for 2 years (2018-2019)
- EU grant, EuroNanoMed III-2016. Project: "RESOLVE - suppression of immunopathology by nanoparticle delivery of mRNA to monocytes" € 255.301,00 for 3 years (2018-2020).

PUBLICATIONS

1. Zanolello P, Rosato A, **Bronte V**, Cerundolo V, Treves S, DiVirgilio F, Pozzan T, Biasi G, Collavo D. Interaction of lymphokine-activate killer cells with susceptible targets does not induce second messenger generation and cytolytic granule exocytosis. *J. Exp. Med.*, 170:665-677, 1989.
2. Zanolello P, Cerundolo V, **Bronte V**, Giunta M, Panozzo M, Biasi G, Collavo D. Resistance of lymphokine-activated T lymphocytes to cell-mediated cytotoxicity. *Cell. Immunol.*, 122:450-460, 1989.
3. Di Virgilio F, **Bronte V**, Collavo D, Zanolello P. Responses of mouse lymphocytes to extracellular adenosine 5'- triphosphate (ATP). *J. Immunol.*, 143:1955-1960 , 1989.
4. Di Virgilio F, Pizzo P, Zanolello P, **Bronte V**, Collavo D. Extracellular ATP as a possible mediator of cytotoxicity. *Immunol. Today*, 11:274-277, 1990.
5. Zanolello P, **Bronte V**, Rosato A, Pizzo P, Di Virgilio F. Responses of mouse lymphocytes to extracellular ATP. II. Extracellular ATP causes cell type-dependent lysis and DNA fragmentation. *J. Immunol.*, 145:1545-1550, 1990.
6. Zanolello P, Vallerani E, **Bronte V**, Rosato A, Chieco-Bianchi L, Collavo D. Tolerance induction in adult mice intrathymically injected with Moloney murine leukemia virus and treated with cyclophosphamide. *J. Immunol. Research*, 2:151-156, 1990.
7. Pizzo P, Zanolello P, **Bronte V**, Di Virgilio F. Extracellular ATP causes lysis of mouse thymocytes and activates a plasma membrane ion channel. *Biochem. J.*, 274:139-144, 1991.
8. Pizzo P, Murgia M, Zambon A, Zanolello P, **Bronte V**, Di Virgilio F. Role of P2z purinergic receptors in ATP-mediated killing of TNF-sensitive and TNF-resistant L929 fibroblasts. *J. Immunol.*, 149:3372-3378, 1992.
9. Zanolello P, Rosato A, **Bronte V**, Mandruzzato S, Cerundolo V, Collavo D. Anti-tumor efficacy of lymphokine-activated killer cells loaded with ricin against experimentally-induced lung metastases. *Cancer Immunol. Immunother.*, 35:27-32, 1992.
10. Rosato A, **Bronte V**, Pollis F, Mandruzzato S, Zambon A, Zanolello P, Collavo D. The in vivo role of Leukocyte Function-Associated Antigen-1 (LFA-1) in cytotoxic cell activity against tumors induced by the retroviral complex M-MSV/M-MuLV. *Leukemia*, 6, suppl.3:166s-167s, 1992.
11. Pollis F, Rosato A, **Bronte V**, Mandruzzato S, Zambon A, Zambello R, Pizzo P, Zanolello P. Interaction of Large Granular Lymphocytes with susceptible target does not induce second messenger generation and cytolytic granule exocytosis. *Leukemia*, 6, suppl.3:166s-167s, 1992.
12. Pollis F, **Bronte V**, Mandruzzato S, Rosato A, Zambon A, Zanolello P, Zambello R, Callegaro L, Collavo D. Inhibition of CTL-line lysis after Gangliosides treatment. *Pharmacological Research*, 26, suppl. 2:190-1, 1992.
13. Mandruzzato S, Rosato A, **Bronte V**, Pollis F, Zambon A, Zanolello P, Collavo D. Therapeutical effect of 4'- deoxy-4'iododoxorubicin-loaded LAK cells in mice bearing lung metastases. *Pharmacological Research*, 26, suppl. 2:124-125, 1992.
14. Rosato A, **Bronte V**, Mandruzzato S, Zambon A, Calderazzo F, Biasi G, Zanolello P, Collavo D. Role of adhesion molecules in the immune reaction to M-MSV-induced tumors. *Int. J. Cancer*, 7:24-27, 1992.
15. **Bronte V**, Zanolello P, Rosato A, Zambon A, Mandruzzato S, Pizzo P, Di Virgilio F, Collavo D. Synergistic effect of extracellular 5'-adenosine triphosphate and Tumor Necrosis Factor

- on DNA degradation. *Cell. Immunol.*, 152:110-119, 1993.
16. Mandruzzato S, Rosato A, **Bronte V**, Zanovello P, Amboldi N, Ballinari D, Collavo D. Adoptive transfer of lymphokine-activated killer cells loaded with 4'-deoxy-4'-iododoxorubicin. Therapeutic effect in mice bearing lung metastases. *Cancer Res.*, 54:1016-1020, 1994.
 17. Zambon A, **Bronte V**, Di Virgilio F, Hanau S, Steinberg TH, Collavo D, Zanovello P. Role of extracellular ATP in cell-mediated cytotoxicity. A study with ATP-sensitive and ATP-resistant macrophages. *Cell. Immunol.*, 156:458-467, 1994.
 18. Rosato A, Zambon A, Mandruzzato S, **Bronte V**, Macino B, Calderazzo F, Collavo D, Zanovello P. Inhibition of protein tyrosine phosphorylation prevents T-cell mediated cytotoxicity. *Cell. Immunol.*, 159:294-305, 1994.
 19. Wang M, **Bronte V**, Chen PW, Gritz L, Panicali D, Rosenberg SA, Restifo NP. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. *J. Immunol.*, 154:4685-4692, 1995.
 20. **Bronte V**, Tsung K, Rao JB, Chen PW, Wang M, Rosenberg SA, Restifo NP. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. *J. Immunol.*, 154:5282-5292, 1995.
 21. Wang M, Chen PW, **Bronte V**, Zhai Y, Rosenberg SA, Restifo NP. Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor antigen. *J. Immunother.*, 18:139-146, 1995.
 22. Di Virgilio F, Zanovello P, Zambon A, **Bronte V**, Pizzo P, Murgia M. Cell membrane receptors for extracellular ATP: a new family of apoptosis-signalling molecules. *Fund. Clin. Immunol.*, 3:80-81, 1995.
 23. Rosato A, Mandruzzato S, **Bronte V**, Zambon A, Macino B, Calderazzo F, Zanovello P, Collavo D. Role of anti-LFA-1 and anti-ICAM-1 combined MAb treatment in the rejection of tumors induced by Moloney murine sarcoma virus (M-MSV). *Int. J. Cancer*, 61:355-362, 1995.
 24. **Bronte V**. Molecular genetics of cancer. Gene therapy and other novel therapeutic approaches. *Cancer*, 76:1878-1881, 1995.
 25. Rosato A, Zambon A, Macino B, Mandruzzato S, **Bronte V**, Milan G, Zanovello P, Collavo D. Anti-L-selectin monoclonal antibody treatment in mice enhances tumor growth by preventing CTL sensitization in peripheral lymph nodes draining the tumor area. *Int. J. Cancer*, 65:847-851, 1996.
 26. Chen PW, Wang M, **Bronte V**, Zhai Y, Rosenberg SA, Restifo NP. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. *J. Immunol.*, 156:238-245, 1996.
 27. **Bronte V**, Macino B, Zambon A, Rosato A, Mandruzzato S, Zanovello P, Collavo D. Protein tyrosine kinases and phosphatases control apoptosis induced by extracellular adenosine 5'-triphosphate. *Biochem. Biophys. Res. Commun.*, 218:344-351, 1996.
 28. Rao JB, Chamberlain RS, **Bronte V**, Carroll MW, Irvine K, Moss B, Rosenberg SA, Restifo NP. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines. Enhancement by simultaneous B7-1 expression. *J. Immunol.*, 156:3357-3365, 1996.
 29. Chamberlain RS, Carroll MW, **Bronte V**, Hwu P, Warren S, Yang JC, Nishimura M, Moss B, Rosenberg SA, Restifo NP. Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. *Cancer Res.*, 56:2832-2836, 1996.
 30. **Bronte V**, Carroll MW, Goletz TJ, Wang W, Overwijk WW, Marincola F, Rosenberg SA, Moss

- B, Restifo NP. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. *Proc. Natl. Acad. Sci. USA*, 94:3183-3188, 1997.
31. Pericle F, Kirken R A, **Bronte V**, Sconocchia G, DaSilva L, Segal DM. Immunocompromised tumor-bearing mice show a selective loss of STAT5a/b expression in T and B lymphocytes. *J. Immunol.*, 159:2580-2585, 1997.
 32. **Bronte V**, Wang M, Overwijk WW, Surman DR, Pericle F, Rosenberg SA, Restifo NP. Apoptotic death of CD8⁺ T lymphocytes after immunization: induction of a suppressive population of Mac-1⁺/Gr-1⁺ cells, *J. Immunol.*, 161:5313-5320, 1998.
 33. **Bronte V**, Chappell DB, Apolloni E, Cabrelle A, Wang M, Hwu P, Restifo NP. Unopposed production of GM-CSF by tumors inhibits CD8⁺ T cell responses by dysregulating antigen presenting cell maturation. *J. Immunol.*, 162:5728-5737, 1999.
 34. Kaufman HL, Rao JB, Irvine KR, **Bronte V**, Rosenberg SA, Restifo NP. Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model, *J. Immunother.*, 22:489-496, 1999.
 35. Lollini PL, and **Bronte V**. The immunotherapy of cancer: understanding the mechanisms through animal models. *Minerva Biotech.*, 11:283-294, 1999.
 36. **Bronte V**, Apolloni E, Ronca R, Zamboni P, Overwijk WW, Surman DR, Restifo NP, Zanovello P. Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. *Cancer Res.*, 60:253-258, 2000.
 37. **Bronte V**, Apolloni E, Cabrelle A, Ronca R, Serafini P, Zamboni P, Restifo NP, Zanovello P. Identification of a CD11b⁺/Gr-1⁺/CD31⁺ myeloid progenitor capable of activating or suppressing CD8⁺ T cells. *Blood*, 96:3838-3846, 2000.
 38. Apolloni E, **Bronte V**, Mazzoni A, Serafini P, Cabrelle A, Segal DM, Young HO, Zanovello P. Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes. *J. Immunol.*, 165:6723-6730, 2000.
 39. Bocchia M, **Bronte V**, Colombo MP, De Vincentiis A, Di Nicola M, Forni G, Lanata L, Lemoli RM, Massaia M, Rondelli D, Zanon P, Tura S. Antitumor vaccination: where we stand. *Haematologica*, 85:1172-206, 2000.
 40. Mendiratta KS, Thai G, Eslahi NK, Thull N, Matar M, **Bronte V**, Pericle F. Therapeutic tumor immunity induced by poly-immunization with melanoma antigens gp100 and TRP-2. *Cancer Res.*, 61:859-863, 2001.
 41. **Bronte V**. Genetic vaccination for the active immunotherapy of cancer. *Curr. Gene Ther.*, 1:53-100, 2001.
 42. **Bronte V**, Serafini P, Apolloni E, Zanovello P. Tumor-induced dysfunctions caused by myeloid suppressor cells. *J. Immunother.*, 24:431-46, 2001.
 43. Milan G, Apolloni A, **Bronte V**, Dalla Santa S, Macino B, Mandruzzato S, Rosato A, Quintieri L, Serafini P, Zoso A, Zanovello P. Antitumors DNA vaccines, *J. Immunol. Immunopharmacol.*, 21:86-93, 2001.
 44. Mazzoni A, **Bronte V**, Visintin A, Spitzer JH, Apolloni E, Serafini P, Zanovello P, Segal DM. Myeloid suppressor lines inhibit T cell responses by a nitric oxide dependent mechanism. *J. Immunol.*, 168:689-95, 2002.
 45. **Bronte V**, Serafini P, Marigo I, De Santo C, Tosello V, Mazzoni A, Segal DM, Staib C, Lowel M, Sutter G, Colombo MP, Zanovello P. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. *J. Immunol.*, 170:270-8, 2003.
 46. **Bronte V**, Serafini P, Mazzoni A, Segal DM, Zanovello P. L-arginine metabolism in myeloid

cells controls T lymphocyte functions. *Trends Immunol.*, 24:301-5, 2003.

47. Cozzi E, Cadrobbi R, Baldan N, Dedja A, Calabrese F, Castagnaro M, Fante F, Iacopetti I, Ravarotto L, Carraro P, **Bronte V**, De Santo C, Busetto R, Plebani M, Cancellotti FM, Rigotti P, Thiene G, Ancona E. Methotrexate for immunosuppression in life-supporting pig-to-cynomolgus monkey renal xenotransplantation. *Xenotransplantation*, 10: 587-595, 2003.
48. Serafini P, De Santo C, Marigo I, Cingarlini S, Dolcetti L, Gallina G, Zanovello P, **Bronte V**. Derangement of immune responses by myeloid suppressor cells. *Cancer. Immunol. Immunother.*, 53:64-72, 2003.
49. **Bronte V**, Cingarlini S, Apolloni E, Serafini P, Marigo I, De Santo C, Macino B, Marin O, Zanovello P. Effective genetic vaccination with a widely shared endogenous retroviral tumor antigen requires CD40 stimulation during tumor rejection phase. *J. Immunol.*, 171:6396-405, 2003.
50. Sfondrini L, Besusso D, **Bronte V**, Macino B, Rossini A, Colombo MP, Menard S, Balsari A. CpG-Oligodeoxynucleotides activate tyrosinase-related protein 2-specific T lymphocytes but do not lead to a protective tumor-specific memory response. *Cancer Immunol. Immunother.*, 53:697-704, 2004.
51. Serafini P, Carbley R, Noonan KA, Tan G, **Bronte V**, Borrello I. High-dose GM-CSF-producing vaccines impair the immune system through the recruitment of myeloid suppressor cells. *Cancer Res.*, 64:6337-43, 2004.
52. De Palma R, Marigo I, Del Galdo F, De Santo C, Serafini P, Cingarlini S, Tüting T, Lenz J, Basso G, Zanovello P, **Bronte V**. Therapeutic effectiveness of recombinant cancer vaccines is associated with a prevalent TCR- α usage by melanoma-specific CD8⁺ T lymphocytes. *Cancer Res.*, 64:8068-8076, 2004.
53. Mocellin S, Mandruzzato S, **Bronte V**, Lise M, Nitti D. Part I: Vaccines for solid tumours . *Lancet Oncology*, 5:681-89, 2004.
54. Mocellin S, Mandruzzato M, **Bronte V**, Marincola F. Correspondence. Cancer vaccines: pessimism in check. *Nat. Med.*, 10:1278-9, 2004.
55. De Santo C, Serafini P, Marigo I, Dolcetti L, Bolla M, Del Soldato P, Melani C, Guiducci C, Colombo MP, Iezzi M, Musiani P, Zanovello P, **Bronte V**. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. *Proc. Natl. Acad. Sci. USA*, 102:4185-4190, 2005.
56. **Bronte V**, Kasic T, Gri G, Gallana K, Borsellino G, Marigo I, Battistini L, Iafrate M, Prayer-Galetti T, Pagano F, Viola A. Boosting anti-tumor responses of T lymphocytes infiltrating human prostate cancers. *J. Exp. Med.*, 201:1257-1268, 2005.
57. Avogadri F, Martinoli C, Petrovska L, Chiodoni C, Transidico P, **Bronte V**, Colombo MP, Dougan G, Rescigno M. Cancer immunotherapy based on killing of Salmonella-infected tumor cells. *Cancer Res.*, 65:3615-21, 2005.
58. **Bronte V**, Zanovello P. Regulation of immune responses by L-arginine metabolism. *Nat. Rev. Immunol.*, 5:641-54, 2005.
59. Mocellin S, Mandruzzato S, Zanovello P, **Bronte V**. Cancer rejection by the immune system: forcing the check-points of tumor immune escape. *Drug Discovery Today: Disease Mechanisms*, 2:191-197, 2005.
60. Serafini P, Borrello I, **Bronte V**. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. *Seminars Cancer Biol.*, 16:53-65, 2006.
61. Biswas SK, Gangi L, Paul S, Schioppa T, Sacconi A, Sironi M, Bottazzi B, Doni A, **Bronte V**,

- Pasqualini F, Vago L, Nebuloni M, Mantovani A, Sica A. A distinct and unique transcriptional programme expressed by tumor-associated macrophages: defective NF- κ B and enhanced IRF-3/STAT1 activation. *Blood*, 107:2112-22, 2006.
62. Orabona C, Puccetti P, Vacca C, Biccato S, Luchini A, Fallarino F, Bianchi R, Perruccio K, Velardi A, **Bronte V**, Fioretti MC, Grohmann U. Towards the identification of a tolerogenic signature in IDO-competent dendritic cells. DAP12 and IRF-8 regulate tryptophan catabolism. *Blood*, 107:2846-54, 2006.
 63. **Bronte V**, Cingarlini S, Marigo I, De Santo C, Gallina G, Dolcetti L, Ugel S, Peranzoni E, Mandruzzato S, Zanovello P. Leukocyte infiltration in cancer creates an unfavorable environment for antitumor immune responses: a novel target for therapeutic intervention. *Immunol Invest.*, 35:327-57, 2006.
 64. Mocellin S, **Bronte V**, Nitti D. Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities. *Med. Res. Rev.*, 27:317-52, 2007.
 65. Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, Colombo MP, Basso G, Brombacher F, Borrello I, Zanovello P, Biccato S, **Bronte V**. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8⁺ T cells. *J. Clin. Invest.*, 116:2777-2790, 2006.
 66. Serafini P, Meckel K, Kelso M, Noonan KA, Califano J, Koch W, Dolcetti L, **Bronte V**, Borrello, I. Chronic phosphodiesterase-5 inhibition augments endogenous anti-tumor immunity by reducing myeloid-derived suppressor cell function. *J. Exp. Med.*, 203:2691-702, 2006.
 67. Gabrilovich DI, **Bronte V**, Chen SH, Colombo MP, Ochoa A, Ostrand-Rosenber S, Schreiber H. The terminology issue for myeloid-derived suppressor cells. *Cancer Res.*, 67:425, 2007.
 68. Sica A, **Bronte V**. Altered macrophage differentiation and immune dysfunctions during tumor development. *J. Clin. Invest.*, 117:1155-66, 2007.
 69. Viola A, **Bronte V**. Metabolic mechanisms of cancer-induced inhibition of immune responses. *Semin Cancer Biol.*, 17:309-16, 2007.
 70. Peranzoni E, Marigo I, Dolcetti L, Ugel S, Sonda N, Taschin E, Mantelli B, **Bronte V**, Zanovello P. Role of arginine metabolism in immunity and immunopathology. *Immunobiology*, 212:795-812, 2008.
 71. Marigo I, Dolcetti L, Serafini P, Zanovello P, **Bronte V**. Tumor-induced tolerance and immune suppression by myeloid-derived suppressor cells. *Immunol Rev.*, 222:162-79, 2008.
 72. Dolcetti L, Marigo I, Mantelli B, Peranzoni E, Zanovello P, **Bronte V**. Myeloid-derived suppressor cell role in tumor-related inflammation. *Cancer Lett.*, 267:216-25, 2008.
 73. **Bronte V**. Th17 and cancer: friends or foes? *Blood*, 112:214, 2008.
 74. Mennuni C, Ugel S, Mori F, Cipriani B, Iezzi M, Pannellini M, Lazzaro D, Ciliberto G, La Monica N, Zanovello P, **Bronte V**, Scarselli E. Immunosurveillance by telomerase-based vaccination. *Cancer Res.*, 68:9865-74, 2008.
 75. Tosello V, Zamarchi R, Merlo A, Gorza M, Piovan E, Mandruzzato S, **Bronte V**, Wang X, Ferrone S, Amadori A, Zanovello P. Differential expression of constitutive and inducible proteasome subunits in human monocyte-derived DC differentiated in the presence of IFN- α or IL-4. *Eur J Immunol.* 39:56-66, 2009.
 76. Mandruzzato S, Solito S, Falisi E, Francescato S, Chiarion-Sileni V, Mocellin S, Zanon A, Rossi CR, Nitti D, **Bronte V**, Zanovello P. IL4R α ⁺ myeloid-derived suppressor cell expansion in cancer patients. *J Immunol.* 182:6562-8, 2009.

77. **Bronte V**, Mocellin S. Suppressive influences in the immune response to cancer. *J Immunother.* 32:1-11, 2009.
78. Persano L, Moserle L, Esposito G, **Bronte V**, Barbieri V, Iafrate M, Gardiman MP, Larghero P, Pfeffer U, Naschberger E, Stürzl M, Indraccolo S, Amadori A. Interferon-alpha counteracts the angiogenic switch and reduces tumor cell proliferation in a spontaneous model of prostatic cancer. *Carcinogenesis*, 30:851-60, 2009.
79. Ugel S, Delpozzi F, Desantis G, Papalini F, Simonato F, Sonda N, Zilio S, **Bronte V**. Therapeutic targeting of myeloid-derived suppressor cells. *Curr Opin Pharmacol.*, 9:470-81, 2009.
80. **Bronte V**. Myeloid-derived suppressor cells in inflammation: uncovering cell subsets with enhanced immunosuppressive functions. *Eur J Immunol.*, 39:2670-2, 2009.
81. Ugel S, Zoso A, De Santo C, Li Y, Marigo I, Ugel S, Zanovello P, Scarselli E, Cipriani B, Schneck JP, Oelke M, and **Bronte V**. In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer. *Cancer Res.*, 69:9376-84, 2009.
82. Dolcetti L, Peranzoni E, Ugel S, Marigo I, Fernandez Gomez A, Mesa C, Geilich M, Winkels G, Traggiai E, Casati A, Grassi F, **Bronte V**. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. *Frontline paper. Eur. J. Immunol.*, 40:22-35, 2009.
83. Ugel S, Scarselli E, Iezzi M, Mennuni C, Pannellini T, Calvaruso F, Cipriani B, De Palma R, Ricci-Vitiani L, Peranzoni E, Musiani P, Zanovello P, **Bronte V**. Autoimmune B cell lymphopenia following successful adoptive therapy with telomerase-specific T lymphocytes., *Blood*, 115:1374-84, 2010.
84. Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, Mandruzzato S, **Bronte V**. Myeloid-derived suppressor cell heterogeneity and subset definition. *Curr. Opin. Immunol.*, 22:238-44, 2010.
85. Grohmann U, **Bronte V**. Control of immune response by amino acid metabolism. *Immunol. Rev.*, 236:243-264, 2010.
86. Marigo I, Bosio E, Solito S, Mesa C, Fernandez A, Dolcetti L, Ugel S, Sonda N, Biciato S, Falisi E, Calabrese F, Basso G, Zanovello P, Cozzi E, Mandruzzato S, **Bronte V**. Tumor-induced tolerance and immune suppression depend on C/EBP β transcription factor. *Immunity*, 32:790-802, 2010.
87. Ruggero K, Corradin A, Zanovello P, Amadori A, **Bronte V**, Ciminale V, D'Agostino DM Role of microRNAs in HTLV-1 infection and transformation. *Mol. Aspects Med.*, 31:367-82, 2010.
88. Martini M, Testi MG, Pasetto M, Picchio MC, Innamorati G, Mazzocco M, Ugel S, Cingarlini S, **Bronte V**, Zanovello P, Krampera M, Mosna F, Cestari T, Riviera AP, Brutti N, Barbieri O, Matera L, Tridente G, Colombatti M, Sartoris S. IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. *Vaccine*, 28:3548-57, 2010.
89. Di Camillo B, Sanavia T, Iori E, **Bronte V**, Roncaglia E, Maran A, Avogaro A, Toffolo G, Cobelli C. The transcriptional response in human umbilical vein endothelial cells exposed to insulin: a dynamic gene expression approach. *PLoS One*. Dec 22;5: e14390, 2010.
90. Dolcetti L, Peranzoni E, **Bronte V**. Measurement of myeloid cell immune suppressive activity. *Curr Protoc Immunol*. 2010 Nov;Chapter 14:Unit 14.17.
91. Fernández A, Mesa C, Marigo I, Dolcetti L, Clavell M, Oliver L, Fernández LE, **Bronte V**. Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant. *J. Immunol.*, 186:264-74, 2011.

92. Adeegbe D, Serafini P, **Bronte V**, Zoso A, Ricordi C, Inverardi L. In vivo induction of myeloid suppressor cells and CD4⁺Foxp3⁺ T regulatory cells prolongs skin allograft survival in mice. *Cell Transplant.*, 20:941-54, 2011.
93. Sonda N, Chioda M, Zilio S, Simonato F, **Bronte V**. Transcription factors in myeloid-derived suppressor cell generation. *Curr. Opin. Immunol.*, 23:279-85, 2011.
94. Rotondo R, Bertolotto M, Barisione G, Astigiano S, Mandruzzato S, Ottonello L, Dallegri F, **Bronte V**, Ferrini S, Barbieri O. Exocytosis of azurophil and arginase 1-containing granules by activated polymorphonuclear neutrophils is required to inhibit T lymphocyte proliferation. *J. Leukoc. Biol.*, 89:721-7, 2011.
95. Ramonda R, Musacchio E, Campana C, Frigato M, Frallonardo P, Barbieri V, Piccoli A, Valvason C, **Bronte V**, Zanovello P, Punzi L. Immunogenetic aspects of erosive osteoarthritis of the hand in patients from northern Italy. *Scand. J. Rheumatol.*, 40:139-44, 2011.
96. Chioda M, Peranzoni E, Desantis G, Papalini F, Falisi E, Solito S, Mandruzzato S, **Bronte V**. Myeloid cell diversification and complexity: an old concept with new turns in oncology. *Cancer Metastasis Rev.*, 30:27-43, 2011.
97. Hammami I, Chen J, **Bronte V**, De Crescenzo G, Jolicoeur M. Myeloid-derived suppressor cells exhibit two bioenergetic steady-states in vitro. *J. Biotechnol.*, 152:43-8, 2011.
98. **Bronte V**. Tolerogenic pDCs: spotlight on Foxo3. *J. Clin. Invest.*, 121:1247-50, 2011.
99. Solito S, **Bronte V**, Mandruzzato S. Antigen specificity of immune suppression by myeloid-derived suppressor cells. *J. Leukoc. Biol.*, 90:31-6, 2011.
100. Ghisi M, Corradin A, Basso K, Frasson C, Serafin V, Mukherjee S, Mussolin L, Ruggero K, Bonanno L, Guffanti A, De Bellis G, Gerosa G, Stellin G, D'Agostino DM, Basso G, **Bronte V**, Indraccolo S, Amadori A, Zanovello P. Modulation of microRNA expression in human T-cell development: targeting of Notch3 by miR-150. *Blood*, 117:7053-62, 2011.
101. Kasic T, Colombo P, Soldani C, Wang CM, Miranda E, Roncalli V, **Bronte V**, Viola A. Modulation of human T cell functions by reactive nitrogen species. *Eur. J. Immunol.*, 41:1843-9, 2011.
102. Molon B, Ugel S, Del Pozzo F, Soldani C, Zilio S, Avella D, De Palma A, Mauri P, Monegal A, Rescigno M, Savino B, Colombo P, Jonjic N, Pecanic S, Lazzarato L, Fruttero R, Gasco A, **Bronte V**, Viola A. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. *J. Exp. Med.*, 208:1949-62, 2011.
103. Solito S, Falisi E, Diaz-Montero CM, Doni A, Pinton L, Rosato A, Francescato S, Basso G, Zanovello P, Onicescu G, Garrett-Mayer E, Montero AJ, **Bronte V**, Mandruzzato S. A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. *Blood*, 118:2254-65, 2011.
104. Montero AJ, Diaz-Montero CM, Kyriakopoulos CE, **Bronte V**, Mandruzzato S. Myeloid-derived suppressor cells in cancer patients: a clinical perspective. *J Immunother.*, 35:107-15, 2012.
105. Gabrilovich DI, Ostrand-Rosenberg S, **Bronte V**. Coordinated regulation of myeloid cells by tumours. *Nat Rev Immunol.*, 12:253-68, 2012.
106. Hammami I, Bertrand M, Chen J, **Bronte V**, De Crescenzo G, Jolicoeur M. Nitricoxide affects immune cells bioenergetics: Long-term effects of nitric-oxide derivatives on leukaemic Jurkat cell metabolism. *Immunobiology*, 217:808-15, 2012.
107. Molon B, Viola A, **Bronte V**. Smoothing T cell roads to the tumor: Chemokine post-translational regulation. *Oncoimmunology*, 1:390-392, 2012.

108. Hammami I, Chen J, Murschel F, **Bronte V**, De Crescenzo G, Jolicoeur M. Immunosuppressive activity enhances central carbon metabolism and bioenergetics in myeloid-derived suppressor cells in vitro models. *BMC Cell Biol.*, 13:18, 2012.
109. Viola A, Sarukhan A, **Bronte V**, Molon B. The pros and cons of chemokines in tumor immunology. *Trends Immunol.*, 33:496-504, 2012.
110. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, Hilf N, Schoor O, Fritsche J, Mahr A, Maurer D, Vass V, Trautwein C, Lewandowski P, Flohr C, Pohla H, Stanczak JJ, **Bronte V**, Mandruzzato S, Biedermann T, Pawelec G, Derhovanessian E, Yamagishi H, Miki T, Hongo F, Takaha N, Hirakawa K, Tanaka H, Stevanovic S, Frisch J, Mayer-Mokler A, Kirner A, Rammensee HG, Reinhardt C, Singh-Jasuja H. Multi-peptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. *Nat Med.*, 18:1254-1261, 2012.
111. Hammami I, Chen J, **Bronte V**, Decrescenzo G, Jolicoeur M. I-glutamine is a key parameter in the immunosuppression phenomenon. *Biochem Biophys Res Commun.* 425:724-9, 2012.
112. Ugel S, Peranzoni E, Desantis G, Chioda M, Walter S, Weinschenk T, Ochando JC, Cabrelle A, Mandruzzato S, **Bronte V**. Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. *Cell Rep.*, 2:628-39, 2012.
113. Beghini A, Corlazzoli F, Del Giacco L, Re M, Lazzaroni F, Brioschi M, Valentini G, Ferrazzi F, Ghilardi A, Righi M, Turrini M, Mignardi M, Cesana C, **Bronte V**, Nilsson M, Morra E, Cairoli R. Regeneration-associated WNT signaling is activated in long-term reconstituting AC133bright acute myeloid leukemia cells. *Neoplasia*, 14:1236-48, 2012.
114. Zhu Z, Singh V, Watkins SK, **Bronte V**, Shoe JL, Feigenbaum L, Hurwitz AA. High Avidity T cells are Preferentially Tolerized in the Tumor Microenvironment. *Cancer Res.*, 73: 595-604, 2013.
115. Schmidt K, Zilio S, Schmollinger JC, **Bronte V**, Blankenstein T, Willmsky G. Differently immunogenic cancers in mice induce immature myeloid cells that suppress CTL in vitro but not in vivo following transfer. *Blood*, 121:1740-8, 2013.
116. Hickman HD, Reynoso GV, Ngudiankama BF, Rubin EJ, Magadán JG, Cush SS, Gibbs J, Molon B, **Bronte V**, Bennink JR, Yewdell JW. Anatomically restricted synergistic antiviral activities of innate and adaptive immune cells in the skin. *Cell Host Microbe*, 13:155-68, 2013.
117. Sonda N, Simonato F, Peranzoni E, Calì B, Bortoluzzi S, Bisognin A, Wang E, Marincola FM, Naldini L, Gentner B, Trautwein C, Sackett SD, Zanovello P, Molon B, **Bronte V**. miR-142-3p prevents macrophage differentiation during cancer-induced myelopoiesis. *Immunity*, 38:1236-49, 2013.
118. **Bronte V**, Pittet MJ. The spleen in local and systemic regulation of immunity. *Immunity*, 39:806-818, 2013.
119. De Sanctis F, Sandri S, Ferrarini G, Pagliarello I, Sartoris S, Ugel S, Marigo I, Molon B, **Bronte V**. The Emerging Immunological Role of Post-Translational Modifications by Reactive Nitrogen Species in Cancer Microenvironment. *Front Immunol.*, 5:69, 2014.
120. Bianchi G, Vuerich M, Pellegatti P, Marimpietri D, Emionite L, Marigo I, **Bronte V**, Di Virgilio F, Pistoia V, Raffaghello L. ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment. *Cell Death Dis.*, 5:e1135, 2014.
121. Ruggero K, Guffanti A, Corradin A, Sharma VK, De Bellis G, Corti G, Grassi A, Zanovello P, **Bronte V**, Ciminale V, D'Agostino DM. Small Noncoding RNAs in Cells Transformed by

- Human T-Cell Leukemia Virus Type 1: a Role for a tRNA Fragment as a Primer for Reverse Transcriptase. *J Virol.*, 88:3612-22, 2014.
122. Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, **Bronte V**, Chouaib S. PD-L1 is a novel direct target of HIF-1 α , and its blockade under hypoxia enhanced MDSC-mediated T cell activation. *J Exp Med*, 211:781-90, 2014.
 123. Solito S, Marigo I, Pinton L, Damuzzo V, Mandruzzato S, **Bronte V**. Myeloid-derived suppressor cell heterogeneity in human cancers. *Ann N Y Acad Sci.*, 1319:47-65, 2014.
 124. **Bronte V**. Tumor cells hijack macrophages via lactic acid. *Immunol Cell Biol.*, 92:647-9, 2014.
 125. Zoso A, Mazza EM, Bicciato S, Mandruzzato S, **Bronte V**, Serafini P, Inverardi L. Human fibrocytic myeloid-derived suppressor cells express IDO and promote tolerance via Treg-cell expansion. *Eur J Immunol.*, 44:3307-19, 2014.
 126. Schoenen H, Huber A, Sonda N, Zimmermann S, Jantsch J, Lepenies B, **Bronte V**, Lang R. Differential Control of Mincle-Dependent Cord Factor Recognition and Macrophage Responses by the Transcription Factors C/EBP β and HIF1 α . *J Immunol.*, 193:3664-75, 2014.
 127. Ricci C, Mota C, Moscato S, D'Alessandro D, Ugel S, Sartoris S, **Bronte V**, Boggi U, Campani D, Funel N, Moroni L, Danti S. Interfacing polymeric scaffolds with primary pancreatic ductal adenocarcinoma cells to develop 3D cancer models. *Biomater.*, 4:e955386, 2014.
 128. **Bronte V**. Tumors STING Adaptive Antitumor Immunity. *Immunity*, 41:679-81, 2014.
 129. Haverkamp JM, Smith AM, Weinlich R, Dillon CP, Qualls JE, Neale G, Koss B, Kim Y, **Bronte V**, Herold MJ, Green DR, Opferman JT, Murray PJ. Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways. *Immunity*. Dec 18;41(6):947-59, 2014.
 130. Damuzzo V, Pinton L, Desantis G, Solito S, Marigo I, **Bronte V**, Mandruzzato S. Complexity and challenges in defining myeloid-derived suppressor cells. *Cytometry B Clin Cytom.*, 88:77-91, 2015.
 131. Mazza EMC, Zoso A, Mandruzzato S, **Bronte V**, Serafini P, Inverardi L, Bicciato S. Gene expression profiling of human fibrocytic myeloid-derived suppressor cells (f-MDSCs). *Genomics Data*, 2:389-92, 2014.
 132. **Bronte V**, Murray PJ. Understanding Local Macrophage Phenotypes In Disease: Modulating macrophage function to treat cancer. *Nat Med.*, 21:117-9, 2015.
 133. Arina A, **Bronte V**. Myeloid-derived suppressor cell impact on endogenous and adoptively transferred T cells. *Curr Opin Immunol.*, 33:120-5, 2015.
 134. Calì B, Ceolin S, Ceriani F, Bortolozzi M, Agnellini AH, Zorzi V, Predonzani A, **Bronte V**, Molon B, Mammano F. Critical role of gap junction communication, calcium and nitric oxide signaling in bystander responses to focal photodynamic injury. *Oncotarget*. 6:10161-74, 2015.
 135. Mazzocco M, Martini M, Rosato A, Stefani E, Matucci A, Dalla Santa S, De Sanctis F, Ugel S, Sandri S, Ferrarini G, Cestari T, Ferrari S, Zanovello P, **Bronte V**, Sartoris S. Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma. *Immunology*. 146:33-49, 2015.
 136. Conde P, Rodriguez M, van der Touw W, Jimenez A, Burns M, Miller J, Brahmachary M, Chen HM, Boros P, Rausell-Palamos F, Yun TJ, Riquelme P, Rastrojo A, Aguado B, Stein-Streilein J, Tanaka M, Zhou L, Zhang J, Lowary TL, Ginhoux F, Park CG, Cheong C, Brody J, Turley SJ, Lira SA, **Bronte V**, Gordon S, Heeger PS, Merad M, Hutchinson J, Chen SH, Ochando J. DC-SIGN(+) Macrophages Control the Induction of Transplantation Tolerance.

Immunity, 42:1143-1158, 2015.

137. Carbognin L, Pilotto S, Milella M, Vaccaro V, Brunelli M, Calìo A, Cuppone F, Sperduti I, Giannarelli D, Chilosì M, **Bronte V**, Scarpa A, Bria E, Tortora G. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. *PLoS One*. Jun 18;10(6):e0130142, 2015.
138. Noman MZ, Janji B, Hu S, Wu JC, Martelli F, **Bronte V**, Chouaib S. Tumor promoting effects of myeloid derived suppressor cells are potentiated by hypoxia-induced expression of miR-210. *Cancer Res.*, 75:3771-87, 2015.
139. De Sanctis F, Solito S, Ugel S, Molon B, **Bronte V**, Marigo I. MDSCs in cancer: Conceiving new prognostic and therapeutic targets. *Biochim Biophys Acta*, 1865:35-48, 2016.
140. Koehn BH, Apostolova P, Haverkamp JM, Miller JS, McCullar V, Tolar J, Munn DH, Murphy WJ, Brickey WJ, Serody JS, Gabrilovich DI, **Bronte V**, Murray PJ, Ting JP, Zeiser R, Blazar BR. GvHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells. *Blood*, 126:1621-8, 2015.
141. Ochando J, Conde P, **Bronte V**. Monocyte-Derived Suppressor Cells in Transplantation. *Curr Transplant Rep.*, 2:176-183, 2015.
142. Zhu Z, Cuss SM, Singh V, Gurusamy D, Shoe JL, Leighty R, **Bronte V**, Hurwitz AA. CD4+ T Cell Help Selectively Enhances High-Avidity Tumor Antigen-Specific CD8+ T Cells. *J Immunol.*, 195:3482-9, 2015.
143. Ugel S, De Sanctis F, Mandruzzato S, **Bronte V**. Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. *J Clin Invest.*, 125:3365-76, 2015.
144. Astigiano S, Morini M, Damonte P, Fraternali Orcioni G, Cassanello M, Puglisi A, Noonan DM, **Bronte V**, Barbieri O. Transgenic mice overexpressing arginase 1 in monocytic cell lineage are affected by lympho-myeloproliferative disorders and disseminated intravascular coagulation. *Carcinogenesis*, 36:1354-62, 2015.
145. Massari F, Ciccarese C, Calìo A, Munari E, Cima L, Porcaro AB, Novella G, Artibani W, Sava T, Eccher A, Ghimenton C, Bertoldo F, Scarpa A, Sperandio N, Porta C, **Bronte V**, Chilosì M, Bogina G, Zamboni G, Tortora G, Samaratunga H, Martignoni G, Brunelli M. Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis. *Target Oncol*. Jun;11(3):345-51, 2016.
146. Munn DH, **Bronte V**. Immune suppressive mechanisms in the tumor microenvironment. *Curr Opin Immunol.*, 39:1-6, 2016.
147. Pinton L, Solito S, Damuzzo V, Francescato S, Pozzuoli A, Berizzi A, Mocellin S, Rossi CR, **Bronte V**, Mandruzzato S. Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression. *Oncotarget*, 7:1168-84, 2016.
148. Mandruzzato S, Brandau S, Britten CM, **Bronte V**, Damuzzo V, Gouttefangeas C, Maurer D, Ottensmeier C, van der Burg SH, Welters MJ, Walter S. Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study. *Cancer Immunol Immunother.*, 65:161-9, 2016.
149. Arina A, Corrales L, **Bronte V**. Enhancing T cell therapy by overcoming the immunosuppressive tumor microenvironment. *Semin Immunol*. 28:54-63, 2016.
150. **Bronte V**, Bria E. Interfering with CCL5/CCR5 at the Tumor-Stroma Interface. *Cancer Cell*, 29:437-9, 2016.
151. Sasso MS, Lollo G, Pitorre M, Solito S, Pinton L, Valpione S, Bastiat G, Mandruzzato S,

- Bronte V**, Marigo I, Benoit JP. Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy. *Biomaterials*, 96:47-62, 2016.
152. Sandri S, Bobisse S, Moxley K, Lamolinara A, De Sanctis F, Boschi F, Sbarbati A, Fracasso G, Ferrarini G, Hendriks RW, Cavallini C, Scupoli MT, Sartoris S, Iezzi M, Nishimura MI, **Bronte V**, Ugel S. Feasibility of telomerase-specific adoptive T-cell therapy for B-cell chronic lymphocytic leukemia and solid malignancies. *Cancer Res.*, 76:2540-51, 2016.
 153. **Bronte V**, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, Rodriguez PC, Sica A, Umansky V, Vonderheide RH, Gabrilovich DI. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. *Nat Commun.* 7:12150, 2016.
 154. **Bronte V**, Tortora G. Adipocytes and Neutrophils Give a Helping Hand to Pancreatic Cancers. *Cancer Discov.* 6:821-3, 2016.
 155. Marigo I, Zilio S, Desantis G, Mlecnik B, Agnellini AH, Ugel S, Sasso MS, Qualls JE, Kratochvill F, Zanollo P, Molon B, Ries CH, Runza V, Hoves S, Bilocq AM, Bindea G, Mazza EM, Biccato S, Galon J, Murray PJ, **Bronte V**. T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells. *Cancer Cell*, 30:377-90, 2016.
 156. Perico ME, Grasso S, Brunelli M, Martignoni G, Munari E, Moiso E, Fracasso G, Cestari T, Naim HY, **Bronte V**, Colombatti M, Ramarli D. Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells "in vitro" and correlating with progression "in vivo". *Oncotarget*. Nov 8;7(45):74189-74202, 2016.
 157. Trento C, Marigo I, Pievani A, Galleu A, Dolcetti L, Wang CY, Serafini M, **Bronte V**, Dazzi F. Bone marrow mesenchymal stromal cells induce nitric oxide synthase-dependent differentiation of CD11b+ cells that expedite hematopoietic recovery. *Haematologica*. May;102(5):818-825, 2017.
 158. Mondanelli G, Bianchi R, Pallotta MT, Orabona C, Albini E, Iacono A, Belladonna ML, Vacca C, Fallarino F, Macchiarulo A, Ugel S, **Bronte V**, Gevi F, Zolla L, Verhaar A, Peppelenbosch M, Mazza EM, Biccato S, Laouar Y, Santambrogio L, Puccetti P, Volpi C, Grohmann U. A Relay Pathway between Arginine and Tryptophan Metabolism Confers Immunosuppressive Properties on Dendritic Cells. *Immunity*. 46:233-244, 2017.
 159. Zilio S, Vella JL, De la Fuente AC, Daftarian PM, Weed DT, Kaifer A, Marigo I, Leone K, **Bronte V**, Serafini P. 4PD Functionalized Dendrimers: A Flexible Tool for In Vivo Gene Silencing of Tumor-Educated Myeloid Cells. *J Immunol*. 198(10):4166-4177, 2017.
 160. Gnjjatic S, **Bronte V**, Brunet LR, Butler MO, Disis ML, Galon J, Hakansson LG, Hanks BA, Karanikas V, Khleif SN, Kirkwood JM, Miller LD, Schendel DJ, Tanneau I, Wigginton JM, Butterfield LH. Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. *J Immunother Cancer*. 16;5:44, 2017
 161. Mondanelli G, Ugel S, Grohmann U, **Bronte V**. The immune regulation in cancer by the amino acid metabolizing enzymes ARG and IDO. *Curr Opin Pharmacol*. 35:30-39, 2017.
 162. Sandri S, De Sanctis F, Lamolinara A, Boschi F, Poffe O, Trovato R, Fiore A, Sartori S, Sbarbati A, Bondanza A, Cesaro S, Krampera M, Scupoli MT, Nishimura MI, Iezzi M, Sartoris S, **Bronte V**, Ugel S. Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy. *Oncotarget*, 8(50):86987-87001, 2017.

163. **Bronte V.** From Oncogene Interference to Neutrophil Immune Modulation. *Immunity*. 47(4):613-615, 2017.
164. Sharma MD, Rodriguez PC, Koehn BH, Baban B, Cui Y, Guo G, Shimoda M, Pacholczyk R, Shi H, Lee EJ, Xu H, Johnson TS, He Y, Mergoub T, Venable C, **Bronte V**, Wolchok JD, Blazar BR, Munn DH. Activation of p53 in myeloid precursor cells controls differentiation into immunogenic Ly6c+CD103+ monocytic cells in tumors. *Immunity*. 48(1):91-106, 2018.
165. **Bronte V.** The mesenchymal and myeloid regulation of immunity: Power is nothing without control. *Semin Immunol*. 10.1016/j.smim.2018.03.001, 2018.
166. **Bronte V.** The expanding constellation of immune checkpoints: a DNAMic control by CD155. *JCI* 10.1172/JCI121229, 2018.
167. Fiore A, Ugel S, De Sanctis F, Sandri S, Fracasso G, Trovato R, Sartoris S, Solito S, Mandruzzato S, Vascotto F, Hippen KL, Mondanelli G, Grohmann U, Piro G, Carbone C, Melisi D, Lawlor RT, Scarpa A, Lamolinara A, Iezzi M, Fassan M, Biccato S, Blazar BR, Sahin U, Murray PJ, **Bronte V.** Cellular and viral FLIP programs broad immune regulatory transcription in monocytes. *Nat. Comm.*, 2018 in press.
168. Solito S, Pinton L, De Sanctis F, Ugel S, **Bronte V**, Mandruzzato S, Marigo I. Methods to Measure MDSC Immune Suppressive Activity In Vitro and In Vivo. *Curr Protoc Immunol*. 10:e61. doi: 10.1002/cpim.61, 2018.
169. De La Fuente A, Caroli J, Van Simaey D, Zilio S, Mazza EMC, **Bronte V**, Biccato S, Weed DT, Serafini P. RNA aptamers specific for mouse and human tumor infiltrating myeloid cells as universal reagents for the targeted delivery of chemotherapeutics. *Sci. Transl. Med* 2018. Under revision

BOOKS AND MONOGRAPHS

1. Collavo D, Zanovello P, **Bronte V**, Rosato A, Biasi G. Meccanismi molecolari della lisi mediata dai linfociti citotossici. *Aggiornamento del medico*, 14, 720-726, 1990.
2. Zanovello P, Vallerani E, **Bronte V**, Rosato A, Collavo D, Chieco-Bianchi L. Tolerance induction and leukemia development in M-MuLV intrathymically injected adult mice treated with cyclophosphamide. *Arch. Geschwulstforsch.*, 60, 423-428, 1990.
3. Collavo D, Zanovello P, Rosato A, **Bronte V**, Facchinetti A, Biasi G. La risposta immunologica verso antigeni tumorali specifici. In: *I modificatori della risposta biologica*, 15-20, 1991.
4. Zanovello P, Rosato A, **Bronte V**, Cerundolo V, Collavo D. Adoptive immunotherapy of experimental tumors using cytotoxic lymphocytes to carry and deliver toxins. In: *Immunology and Biotechnology*. *Ann. Ist. Sup. Sanità*, V. Colizzi, S. Marini, O. Pugliese Eds 27, 91-95, 1991.
5. Macino B, Zambon A, **Bronte V**, Rosato A, Mandruzzato S, Calderazzo F, Mezzalana S, Zanovello P, Collavo D. Studio dei segnali intracellulari coinvolti nell'induzione della morte cellulare programmata. In: *Immunologia 1994*, Monduzzi Ed., 647-650, 1993.
6. DiVirgilio F, Ferrari D, Munerati M, Falzoni S, Villalba M, **Bronte V**, Zambon A, Zanovello P, Steinberg TH. The P2z receptor and its regulation of macrophage function. In: *Adenosine and adenine nucleotides*, A. Pelleg Ed., Kluwer Press, 1994.
7. Macino B, Tosello V, Mandruzzato S, **Bronte V**, Rosato A, Cingarlini S, Dalla Santa S, De Santo C, Marigo I, Rossi E, Zoso A, Gorza M, Zanovello P. Valutazione citometrica della risposta immunitaria mediata dai linfociti T citotossici. Uso della tecnologia dei tetrameri.

Quaderni di citometria pratica. A cura di G. Basso. Volume n° 2, 2003.

8. Mocellin S, **Bronte V**. Suppressive Influences in the Immune Response to Cancer, in "Principles and Practice of Oncology, FOCUS, Vol. 1, No. 4, Lippincott Williams & Wilkins, 2007.
9. Mandruzzato S, Mocellin S, **Bronte V**. "Arginase, nitric oxide synthase, and novel inhibitors of L-arginine metabolism" in "Cancer Immunotherapy," edited by Drs. George Prendergast and Elizabeth Jaffee, Academic Press, 2007.
10. Serafini P, **Bronte V**. Myeloid-derived suppressor cells in cancer in "Tumor-Induced Immune Suppression. Mechanisms and Therapeutic Reversal", edited by Gabrilovich, Dmitry I and Hurwitz, Arthur A., Springer, 2008.
11. Baadn W, **Bronte V**. Myeloid derived suppressor cells in cancer. In "Innate and adaptive immune regulation and Cancer immunotherapy", edited by Rong-Fu Wang, Springer, 2011.
12. Chioda M, Marigo L, Mandruzzato S, Mocellin S, **Bronte V**. Arginase Nitric Oxide Synthase and Novel Inhibitors of L-arginine Metabolism in Immune Modulation in "Cancer Immunotherapy: Immune Suppression and Tumor Growth", edited by George C. Prendergast and Elizabeth M. Jaffee, 2013.
13. Sasso MS, **Bronte V**, Marigo I. Cancer immune modulation and immunosuppressive cells: current and future therapeutic approaches. In: Alonso MJ and Garcia-Fuentes M. Nano-Oncologicals: new targeting and delivery approaches . Advances in Delivery Science and Technology, 2014, Springer.
14. Serafini P, **Bronte V**. Myeloid-Derived Suppressor Cells in Tumor-Induced T Cell Suppression and Tolerance. In: Gabrilovich DI, Hurwitz AA. Tumor-Induced Immune Suppression: Mechanisms and Therapeutic Reversal, 2014, Springer.
15. De Sanctis F, **Bronte V**, Ugel S. 2016. Tumor-Induced Myeloid-Derived Suppressor Cells. Microbiol Spectrum 4(3):MCHD-0016-2015

INVITED LECTURES AND PRESENTATIONS

1. **V. Bronte**. Cytokines and molecularly defined adjuvants can either enhance or restrain the efficacy of recombinant cancer vaccines. Cytokines as natural adjuvants: perspectives for vaccine development. Istituto Superiore di Sanità, 22-24 April 2002, Rome.
2. **V. Bronte**, P. Serafini, C. DeSanto, I. Marigo, V. Tosello, A. Mazzoni, D.M. Segal, M.P. Colombo, and P. Zanovello. Immune dysfunctions induced by myeloid suppressor cells in tumor-bearing mice. Keystone Symposium on Basic aspects of tumor immunology, February 17-24, 2003, Keystone, USA.
3. **V. Bronte**. L-arginine metabolism in CD11b⁺/Gr-1⁺ myeloid cells restrains T lymphocyte functions. Basic Aspects of Vaccines Meeting, April 28-30, 2004, Bethesda, USA.
4. **V. Bronte**. L-Arginine Catabolism in Myeloid Suppressor Cells as a Tool to Restrain T Cell Response. Immune Evasion, March 25 - 30, 2004, Taos, New Mexico, USA.
5. **V. Bronte**. Animal models. Trends in prostate cancer 2004. What is new? September 24, 2004, Padova.
6. **V. Bronte**. L-arginine metabolism in CD11b⁺/Gr-1⁺ myeloid suppressor cells inhibits T lymphocyte function. IT-2004, 15-19 November, 2004, La Habana, Cuba.
7. **V. Bronte**. Checkpoint manipulation in tumor immunotherapy. ESO Advanced course, Immunology for Oncologists, April 16-18, 2005, Ascona, Switzerland.
8. **V. Bronte**. A critical assessment of the progress of cancer vaccines. Cancer

Vaccines/Adjuvants/Delivery for the Next Decade (CVADD 2005). September, 5-7, 2005, Lisboa, Portugal.

9. **V. Bronte.** Myeloid suppressor cells control T lymphocyte activation during physiological and pathological immune responses. XV Congresso AINI - Associazione Italiana Neuroimmunologia, October, 13-15, 2005, Abbazia di Praglia, Teolo, Italy.
10. **V. Bronte.** L-arginine metabolism in tumor-bearing hosts affects T lymphocyte responsiveness. Joint section SIC-SIICA: Tumor immunology. 47° Congresso nazionale della Società Italiana di Cancerologia. October, 2-5, 2005, Abano Terme, Italy.
11. **V. Bronte.** L-arginine metabolism and immune dysfunction in cancer. CIMT 2006 meets Strategies for Immune Therapy. May 4-5, 2006, Mainz, Germany.
12. **V. Bronte.** Mouse myeloid suppressor cells comprise a peculiar population of inflammatory monocytes. Istituto Superiore di Sanita', Immunotherapy of Cancer: Challenges and Needs, May 24-25, 2006, Rome, Italy.
13. **V. Bronte.** Genetic vaccines for the active immunotherapy of cancer. Biological therapy of cancer, June 21 -24, 2006. Dresden, Germany.
14. **V. Bronte.** Altered L-arginine metabolism in cancers restrains anti-tumor T lymphocyte response. 16th European Congress of Immunology, September 6-9, 2006, Paris, France.
15. **V. Bronte.** Arginine metabolism in myelomonocytic cells affects T lymphocyte response to antigen. 20th Annual Meeting of the European Macrophage and Dendritic Cell Society (EMDS). Immunoregulatory and Antimicrobial Activities of Myeloid Cells, October 5-7, 2006, Freiburg, Germany.
16. **V. Bronte.** Regulation of immune responses by L-arginine metabolism. 6th Beaune Seminar in Transplant Research, October 19-20, 2006, Hospices de Beaune, Beaune, France.
17. **V. Bronte.** Development of novel approaches to overcome immunological dysfunctions in preclinical tumor models. Development and functions of immune system: new insights from the study of mouse models Università degli Studi di Roma "La Sapienza", October 31, 2006, Rome, Italy.
18. **V. Bronte.** Cellule mieloidi soppressive e tumori. Corso di Aggiornamento: "Meccanismi di Immunosoppressione e Immunoterapia dei tumori". IST, Genova, 7 Novembre 2006
19. **V. Bronte.** Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8⁺ T cells. IT-2006: Targeting complexity. November 15-19, 2006, La Habana, Cuba.
20. **V. Bronte.** Correction of altered arginine metabolism to boost antitumor immune response. Italian Melanoma Intergroup 12th annual meeting. November 30 - December 2, 2006, Bari, Italy.
21. **V. Bronte.** Inflammatory monocytes induced by tumors alter T-lymphocyte responsiveness through L-Arginine metabolism. 4th Biennial Molecular Targets in Cancer Therapy: Mechanism & Therapeutic Reversal of Immune Suppression in Cancer. January 25-28, 2007, Sheraton Sand Key Resort, Clearwater Beach, Florida, USA.
22. **V. Bronte.** The dual personality of myeloid-derived suppressor cells. Novel mechanisms of immune tolerance in tumor immunology and stem cell/organ transplantation. February 21, 2007, Bologna, Italy.
23. **V. Bronte.** Special lecture: Myeloid suppressor cells in cancer. 2007 Keystone Symposium. The Potent New Anti-Tumor Immunotherapies, March 28 Marzo - April 2, 2007, Fairmont Banff Springs, Banff, Alberta, Canada.
24. **V. Bronte.** Myeloid-derived suppressor cells in cancer: a novel target for therapeutic

invention. Cancer Immunotherapy meets Strategies for Immunotherapy. 5th Annual meeting April 12-14, 2007, Würzburg, Germany.

25. **V. Bronte.** The dual personality of myeloid-derived suppressor cells. International Seminar Series. Department of Neurosurgery, University Hospital. April 19, 2007, Lund, Sweden.
26. **V. Bronte.** Altered myeloid differentiation and immune dysfunctions in cancer. Seventh International Conference on Progress in Vaccination Against Cancer (PIVAC-7), September 9-11, 2007, Stockholm, Sweden.
27. **V. Bronte.** Immune response regulation by tumor-conditioned myeloid-derived suppressor cells. Regulatory pathways in autoimmunity and cancer, BSI Golden Jubilee Year - BSI Wessex Regional Group. October 2, 2007, Southampton, UK.
28. **V. Bronte.** Altered Macrophage Differentiation and Immune Dysfunction in Tumor Development. Cancer and Inflammation, Annual Symposium of the NCI Center of Excellence in Immunology, October 9-10, 2007, Bethesda, USA.
29. **V. Bronte.** Altered macrophage differentiation and T lymphocyte dysfunctions during tumor development. 40th annual Meeting of the Society of Leukocyte Biology. October 11-13, 2007, Cambridge, USA.
30. **V. Bronte.** Myeloid-Derived Suppressor Cells in Cancer. International Society for the Biological Therapy of Cancer, 22nd Annual meeting. November 2-4, 2007, Boston, USA.
31. **V. Bronte.** The biology and function of myeloid-derived suppressor cells. Inflammation and Cancer, November 8-9, 2007, Milano, Italy.
32. **V. Bronte.** System biology of tumor-associated macrophages. MicroRNA in Biology and Disease, December 4, 2007, Padova, Italy.
33. **V. Bronte.** Myeloid-derived suppressor cells in cancer. Centro Nacional de Biotecnología/CSIC. January 18, 2008, Madrid, Spain.
34. **V. Bronte.** Metabolic restraint of T lymphocyte activation and migration by tumor-conditioned myeloid cells. Integrative cancer genomics. February 11-13, 2008, Munich, Germany.
35. **V. Bronte.** Cancer induced barrier against immune system: myeloid-derived suppressor cells. Immunology of Health and Disease Conference. March 9-14, 2008, Cape Town, South Africa.
36. **V. Bronte.** Dissecting the complexity of myeloid-derived suppressor cells. The tolerigenic nature of tumor-associated inflammation: relevance for LCH? 18th Nikolas Symposium. May 2-5, 2008, Corint, Greece.
37. **V. Bronte.** Myeloid-derived suppressor cells in cancer. British Inflammation Research Association Symposium Inflammation and Cancer. May 23, 2008, London. UK.
38. **V. Bronte.** Cancer-induced barrier to immune response: role of myeloid-derived suppressor cells. Tumor Immunology meets Oncology 4th. May 23-24, 2008, Halle (Saale), Germany.
39. **V. Bronte.** Myeloid-derived suppressor cells in cancer. The Giovanni Armenise-Harvard Foundation 12th Annual Symposium, *Cancer: From Genes and Proteins to Pathways and Therapeutics*. June 20-23, 2008, Stresa, Italy.
40. **V. Bronte.** Myeloid suppressor cells in the regulation of immune responses. Innate immunity and inflammation in transplantation. June 26-27, 2008, Nantes, France.
41. **V. Bronte.** Myeloid-derived suppressor cells in cancer. Cancer Immunology & Immunotherapy 2008: From Discovery to Development to Drug. 16th Annual International Cancer Immunotherapy Symposium, September 15-17, 2008 - New York City, USA.

42. **V. Bronte.** Immunosuppressive networks in cancer. Altered myeloid differentiation and immune dysfunctions in cancer. From Tumor Immunology to Immune Therapy of Cancer (course no 1594). Karolinska Institutet, September 19, 2008, Stockholm, Sweden.
43. **V. Bronte.** Myeloid suppressor cells and immune escape Tumour Immune Escape 2008, Ruggero Ceppellini School of Immunology. October 16-18, 2008, Sorrento, Italy.
44. **V. Bronte.** Tumor-induced barriers to immune assault. IRB Conference Room. October 30, 2008, Bellinzona, Switzerland.
45. **V. Bronte.** Learning tolerance from cancer: the lesson of myeloid-dependent suppression. Tumor Immunology: New Perspectives - AACR Special Conference in Cancer Research. December 2-5, 2008, Miami, USA.
46. **V. Bronte.** Myeloid-derived suppressor cells as negative regulators of the immune response: from cancer to transplantation. Pasteur Institute. December 19, 2008, Paris, France.
47. **V. Bronte.** Origin and function of myeloid-derived suppressor cells Monocyte, macrophage and dendritic cell heterogeneity. March 2-7, 2009 - Treilles, France.
48. **V. Bronte.** Mechanisms of MDSC mediated immune suppression. Molecular targets for cancer therapy: fifth biennial meeting. March 12-15, 2009, Clearwater beach, FL, US.
49. **V. Bronte.** Monocyte and macrophage heterogeneity. Translational Research in Paediatric Rheumatology (TRiPR), Second Conference. Innate Immunity and the Pathogenesis of Rheumatic Diseases, Genoa, Italy, May 6- 8, 2009.
50. **V. Bronte.** Myeloid-derived suppressor cells. The 2nd European Congress of Immunology in September 13-16, 2009, Berlin, Germany.
51. **V. Bronte.** Myeloid-derived suppressor cells. EACR Special Conference: Inflammation and Cancer. September 24-25, 2009, Berlin, Germany.
52. **V. Bronte.** Interazioni tra tumori e midollo osseo nell'induzione di cellule soppressorie di derivazione mieloide. "Microambiente tumorale: ruolo nella progressione neoplastica e nell'immunoregolazione". Genova, October 14, 2009.
53. **V. Bronte.** Learning tolerance from cancer: Lessons from myeloid-derived suppressor cells. Tri-Society Meeting of ICS, ISICR, and SLB. October 18-21, 2009, Lisbon, Portugal.
54. **V. Bronte.** Immunotherapy and immunopathology with either telomerase-specific vaccines or telomerase-specific CTLs. Cancer Vaccine/Adjuvants/Delivery for the next decade (CVAAD) meeting. November, 11-13, Dublin, Ireland.
55. **V. Bronte.** Forced myelopoiesis and immune deviation in cancer. Keystone Symposium on: Molecular and Cellular Biology of Immune Escape in Cancer. February, 7-12, Keystone, US.
56. **V. Bronte.** Myeloid-derived suppressor cells. Keystone Symposium on: The Macrophage: Intersection of Pathogenic and Protective Inflammation. February, 12-17, Banff, Canada.
57. **V. Bronte.** Myeloid-derived suppressor cells: moving from mouse to human. European Society for Clinical Investigation, 44th annual scientific meeting, February, 24-27, Bari, Italy.
58. **V. Bronte.** Cross-talk between cancer and bone marrow for the generation of myeloid-derived suppressor cells: The concept of cancer macroenvironment. 101st AACR Annual Meeting 2010. April 17-21, 2010, Washington, DC, US.
59. **V. Bronte.** Controlling myeloid-derived suppressor cells to enhance cancer immunotherapy. 4^{eme} Journées scientifiques Miltenyi Biotec. From inflammation to immunomodulation in cancer. Cordeliers Institute, June 24, 2010, Paris, France..
60. **V. Bronte.** Interfering with myeloid-dependent suppression to enhance the efficacy of adoptive cell therapy of cancer. Annual Meeting DGfI German Society for Immunology,

September 22-25, 2010, Leipzig, Germany.

61. **V. Bronte.** Interfering with myeloid-dependent suppression to enhance the efficacy of adoptive cell therapy of cancer. DC2010: Forum on Vaccine Science. September, 26-30, 2010, Lugano, Switzerland.
62. **V. Bronte.** Tumor-induced tolerance and immune suppression depend on C/EBP β transcription factor. International Viruses, Genes, and Cancer Conference, September 29 - October 1, 2010 Venice, Italy.
63. **V. Bronte.** Interfering with myeloid-dependent suppression to enhance the efficacy of adoptive cell therapy of cancer. An International Immunopharmacology Conference - Regulatory Myeloid Cells. October 21-24, 2010, Arlington, USA..
64. **V. Bronte.** Immunologia dei tumori: myeloid suppressor cells. Accademia Medica di Roma. March 24, 2011, Rome, Italy.
65. **V. Bronte.** Myeloid-derived suppressor cells in cancer. Annual European Congress of Rheumatology "EULAR 2011". May 25-28, 2011, London, United Kingdom.
66. **V. Bronte.** Chemokine nitration prevents intratumoral infiltration of antigen- specific T cells. 4th Waddensymposium on Novel strategies in immunotherapy of cancer. June 26-29, 2011, Texel, Nederland.
67. **V. Bronte.** Tumor immune evasion based on altered myelopoiesis: cells and molecular mechanisms. 5th Aspen Symposium on Brain Tumor ImmunoTherapy. July 31 – August 3, 2011, Limelight Lodge Aspen, Colorado, USA.
68. **V. Bronte.** Targeting myeloid-dependent suppression to improve cancer immunotherapy. 5th Aspen Symposium on Brain Tumor ImmunoTherapy. July 31 – August 3, 2011, Limelight Lodge Aspen, Colorado, USA.
69. **V. Bronte.** Post-translational chemokine modification in cancer: a strategy to control myeloid and lymphoid cell recruitment. International meeting Chemokines and chemokine receptors in cancer: role of microenvironment, September 26-27, 2011, Napoli, Italy.
70. **V. Bronte.** Interfering with myeloid-dependent suppression to enhance the efficacy of cancer immunotherapy. Joint annual meeting SIICA, September 28 – October 1, 2011, Riccione, Italy.
71. **V. Bronte.** Post-translational chemokine modification prevents intratumoural infiltration of antigen-specific T cells. Progress in vaccination against cancer – PIVAC 2011, October 10-13, 2011, Copenhagen, Denmark.
72. **V. Bronte.** Pancreatic carcinoma and immunity, escape from the immune system: from bench to bedside. XXV Congresso AISP, October 13-15, 2011, Peschiera del Garda (VR), Italy.
73. **V. Bronte.** Interfering with the mechanisms of myeloid-dependent immune suppression in cancer: evidence in mice and humans, ESCII/NIBIT Meeting 2011, New perspectives in the immunotherapy of cancer, October 19-22, 2011, Siena, Italy.
74. **V. Bronte.** Post-translational chemokine modification prevents intratumoural infiltration of antigen-specific T cells. SITC Cancer Conference, November 4-6, 2011, North Bethesda, MD, USA.
75. **V. Bronte.** Post-translational chemokine modification prevents intratumoural infiltration of antigen-specific T cells. NCRI Cancer Conference, November 6-9, 2011, Liverpool, United Kingdom.
76. **V. Bronte.** Cancer and immunosuppression. 2nd EFIS-EJI Intensive Educational Course in Clinical Immunology, November 28-30, 2011, Paris, France.

77. **V. Bronte.** Cancer macroenvironment and immune evasion. International Symposium Changing the microenvironment: new strategies for immunotherapy, March 21-22, 2012, Pamplona, Spain.
78. **V. Bronte.** L'allergologia e immunologia nel terzo millennio: from bedside to bench, dalla clinica alla proteo mica. 111Congresso Nazionale della Federazione delle Società Italiane di Immunologia, Allergologia ed Immunologia Clinica (IFIACI), May 2-5, 2012, Verona, Italy.
79. **V. Bronte.** Applicazioni in oncologia e immunologia. Corso avanzato di citometria a flusso. May 22-23, 2012, Verona, Italy.
80. **V. Bronte.** "The cancer macroenvironment modulates adaptive immunity against cancer". Immunology and Medicine Seminars, May 31 – June 2, 2012, Cambridge, United Kingdom.
81. **V. Bronte.** "Interfering with tumor-induced myelopoiesis to enhance adoptive immunotherapy of cancer", Immunity and Inflammation in Disease", 7th International HBGP Student Council Symposium, 2012, June 7-8, Helsinki, Finland.
82. **V. Bronte.** "Cancer-induced peripheral tolerance occurs in a specialized splenic niche", Center for Cancer Immunology Research Grand Rounds Seminar Series, June 13-15, 2012, Houston, Texas, USA.
83. **V. Bronte.** "CCL2 orchestrates a tolerogenic environment in the spleen of tumor-bearing hosts", EMDS European Macrophage and Dendritic Cell Society, September 1-3, 2012, Debrecen, Hungary.
84. **V. Bronte.** "A tolerogenic environment in the spleen of tumor-bearing hosts", European Congress of Immunology, September 1-5, 2012, Glasgow, Scotland.
85. **V. Bronte.** "CCL2 orchestrates a tolerogenic environment in the spleen of tumor-bearing hosts ", Joint Annual Meeting of the International Cytokine Society (ICS) and the International Society for Interferon and Cytokine Research (ISICR), September 11-14, 2012, Geneva, Switzerland.
86. **V. Bronte.** "A tolerogenic environment in the spleen of tumor-bearing hosts", Cancer Research Institute - From Milestones to Medicines: Translating Tumor Immunology Research into Immunotherapies, October 1-3, 2012, New York, USA.
87. **V. Bronte.** "Chemotherapy Alters a Tolerogenic Environment in the Spleen of Tumor-Bearing Hosts", SITC Workshop Faculty, Society for Immunotherapy of Cancer, October 24-25, 2012, North Bethesda, MD, USA
88. **V. Bronte.** "A tolerogenic environment in the spleen of tumor-bearing hosts", Lund Immunology Seminar Series, Lund University, January 20-21, 2013, Lund, Sweden.
89. **V. Bronte.** "Myeloid Derived Suppressor Cells", Keystone Symposia, Cancer Immunology and Immunotherapy (J4), Jan 27 - Feb 1, 2013, Vancouver, BC, Canada.
90. **V. Bronte.** "Control of tumor-induced immunoregulatory network by microRNAs", Roche Nature Medicine Immunology Symposium, April 28-30, 2013, Buonas, Switzerland.
91. **V. Bronte.** "Control of tumor-induced immunoregulatory network by microRNAs", CIMT Annual International Immunology Meeting 2013, May 14-16, 2013, Mainz, Germany.
92. **V. Bronte.** "Tissue Remodeling: Learning from Tumor Microenvironment", CTS Cell Transplant Society, July 7-11, 2013, Milan, Italy.
93. **V. Bronte.** "Molecular regulation of innate immunity in tumor microenvironment", ICI 2013 15th International Congress of Immunology, August 22-27, 2013, Milan, Italy.
94. **V. Bronte.** "Molecular and metabolic control of adaptive immunity by tumor-induced myelopoiesis", DGf1 Annual Meeting German Society for Immunology, September 12-14, 2013, Mainz, Germany.

95. **V. Bronte.** "Molecular regulation of myeloid-dependent immune suppression", Danish Cancer Society Symposium, September 23-25, 2013, Copenhagen, Denmark.
96. **V. Bronte.** "Modulation of tumor microenvironment by microRNAs", 13th International Conference on Progress in Vaccination Against Cancer – PIVAC-13, October 2-4, 2013, Amsterdam, The Netherlands.
97. **V. Bronte.** "Control of tumor-induced immunoregulatory network by microRNAs", Gene Vaccination in Cancer, October 9-11, 2013, Ascoli Piceno, Italy.
98. **V. Bronte.** "Cancer metabolism and immune suppression", 11th NIBIT Meeting, Cancer Bio-Immunotherapy in Siena, October 17-19, 2013, Siena, Italy.
99. **V. Bronte.** "Molecular regulation of myeloid-dependent immune suppression", Cold Spring Harbor Asia Conference on Cancer Immunology and Immunotherapy, October 28 - November 1, 2013, Suzhou, China.
100. **V. Bronte.** "Introduction to innate immunity", Society for Immunotherapy of Cancer, SITC 2013 Annual Meeting, November 7-10, 2013, National Harbor, MD, U.S.A.
101. **V. Bronte.** "Molecular and metabolic control of adaptive immunity in cancer". University Loyola, November 24-26, 2013, Chicago, U.S.A.
102. **V. Bronte.** "Molecular and metabolic control of adaptive immunity in cancer". Distinguished Lecture Series - The Wistar Institute, November 26-27, 2013, Philadelphia, U.S.A.
103. **V. Bronte.** "Molecular and metabolic control of adaptive immunity in cancer". Seminar at Brunel University, December 16-18, 2013, London, UK.
104. **V. Bronte.** "Role of macrophages in adaptive and innate immunity, models and tools to study macrophage functions", EASL Basic School of Hepatology, January 24-25, 2014, Milan, Italy.
105. **V. Bronte.** "Myeloid-derived suppressor cells: molecular characterization and therapeutic targeting", Seminar in Onco Immunology, February 5-6, 2014, Toulouse, France.
106. **V. Bronte.** "Tumor-Induced Immune Suppression by MDSC", Keystone Symposium 2014, March 9-15, 2014, Vancouver, Canada.
107. **V. Bronte.** "Regulation of intra-tumoral L-arginine metabolism by adaptive immune response", Translational Immunology 2014, April 11-12, 2014, Würzburg, Germany.
108. **V. Bronte.** "Myeloid-derived suppressor cells in cancer", IX National Conference of the Italian Society of Immunology and Allergology (SIICA), May 28-31, 2014, Firenze, Italy.
109. **V. Bronte.** "Molecular and metabolic control of antitumor immunity by myeloid cells", The German Cancer Research Center (DKFZ), June 2-4, 2014, Heidelberg, Germany.
110. **V. Bronte.** "Molecular and metabolic control of adaptive immunity in cancer", King's College, July 1-3, 2014, London, UK.
111. **V. Bronte.** "Regulation of intratumoral L-arginine metabolism by adaptive immunity", Max Delbrück Center for Molecular Medicine, July 7-9, 2014, Berlin, Germany.
112. **V. Bronte.** Chairman at PIVAC, 14th International Conference on Progress In Vaccination Against Cancer, September 24-26, 2014, Rome, Italy.
113. **V. Bronte.** "Myeloid-dependent tolerance: cells and molecular mechanisms", 3rd International Conference on Immune Tolerance 2014, NH Grand Kransapolsky, September 28-30, 2014, Amsterdam, The Netherlands.
114. **V. Bronte.** "Positive and negative myeloid regulators of intra-tumoral adaptive immunity", 3rd Conference of translational medicine on pathogenesis and therapy of immune-

mediated diseases, Workshop SIICA, Italian Society of Immunology Clinical Immunology and Allergology, September 30 – October 1, 2014, Milan, Italy.

115. **V. Bronte.** "Myeloid derived suppressor cells as targets for cancer immunomodulation", Simposio International Symposium on Advanced Oncological Thearpies, October 14-16, 2014, Madrid, Spain.
116. **V. Bronte.** "Molecular and metabolic control of antitumor immunity by myeloid cells", VIII Annual Ri.MED Symposium, October 22, 2014, Milan, Italy.
117. **V. Bronte.** "Myeloid-derived suppressor cells as targets for cancer immune modulation", Joint National Ph.D. Meeting 2014, October 23-25, 2014, Pesaro, Italy.
118. **V. Bronte.** "Introduction to Innate Immunity", SITC 2014 Annual Meeting, November 6-9, 2014, National Harbor, MD, U.S.A.
119. **V. Bronte.** "Molecular and metabolic control of antitumor immunity by myeloid cells", Joint DK Retreat in Cell Death, Inflammation and Immunity, November 30 – December 3, 2014, Obergurgel, Austria.
120. **V. Bronte.** "Interplay between tumor-specific CD8+ T lymphocytes and tumor-infiltrating dendritic cells for the successful immunotherapy of cancer", Istituto Regina Elena, January 29, 2015, Rome, Italy.
121. **V. Bronte.** "Myeloid cells and cancer progression", AACR Annual Meeting 2015, April 17-22, 2015, Philadelphia, USA.
122. **V. Bronte.** "Adoptive cell therapy reprograms tumorinfiltrating myelomonocytic cells", Cell Symposium: Cancer, Inflammation, and Immunity, June 14-16, 2015, Sitges, Spain.
123. **V. Bronte.** "The interplay between L-arginine metabolism and adoptive immunity in cancer", ECI Congress 2015, September 6-9, 2015, Wien, Austria.
124. **V. Bronte.** "The interplay between L-arginine metabolism and adoptive immunity in cancer", The Inaugural International Cancer Immunotherapy Conference: Translating Science Into Survival, September 16-19, 2015, New York, USA.
125. **V. Bronte.** "The interplay between L-arginine metabolism and adoptive immunity in cancer", ICGEB Seminars, October 22, 2015, Trieste, Italy.
126. **V. Bronte.** Co-chairman "Innate Immunity" session, SITC 2015, November 6-8, 2015, National Harbor, MD, USA.
127. **V. Bronte.** "The interplay between L-arginine metabolism and adoptive immunity in cancer", 44th Annual Meeting of JSI, 18-20 novembre 2015, Sapporo, Japan.
128. **V. Bronte.** "Myeloid cells regulation of adaptive immunity in cancer", Second INMUNOTHERCAN Symposium - Inflammation and Immunity in Cancer, December 3-4, 2015, Madrid, Spain.
129. **V. Bronte.** "Plenary lecture: Modulating the tumor environment to enhance cancer immunotherapy", San Raffaele Hospital, December 16, 2015, Milan, Italy.
130. **V. Bronte.** "Myeloid stroma and regulation of adaptive immunity in cancer", Innovative therapy, monoclonal antibodies and beyond - 6th Edition, January 22, 2016, Milan, Italy.
131. **V. Bronte.** "The interplay between L-arginine metabolism and adoptive immunity in cancer", CIIT seminar, January 26, 2016, Innsbruck, Austria.
132. **V. Bronte.** "Immune suppressive mechanisms in cancer microenvironment", World Immune Regulation Meeting – X, March 16-19, 2016, Davos, Switzerland.
133. **V. Bronte.** "Recenti progressi nell'immunoterapia del cancro: la nuova frontiera", La ricerca che cura: presente e futuro – 25° anniversario delegazione AIRC di Gela , April 16, 2016, Gela, Italy.

134. **V. Bronte.** "Immune suppressive and immune stimulating monocytes in cancer", 14th CIMT Annual Meeting, May 10-12, 2016, Mainz, Germany.
135. **V. Bronte.** "ABC di immunologia per oncologi clinici", Carcinoma renale metastatico: continuità terapeutica e approccio multidisciplinare, May 13-14, 2016, Sirmione, Italy.
136. **V. Bronte.** Chairman in "Tumor Immunology 2" session, X National Congress of the Italian Society of Immunology, Clinical Immunology and Allergology (SIICA), May 25-28, 2016, Abano Terme, Italy.
137. **V. Bronte.** "Tumour-induced deviation of myeloid cells", 21st Congress of European Hematology Association, June 9-12, Copenhagen, Denmark.
138. **V. Bronte.** "Immune suppressive and immune stimulating monocytes in cancer environment", Regulatory Myeloid Suppressor Cells Conference, June 16-19, 2016 Philadelphia, USA.
139. **V. Bronte.** "Monocyte-dependent regulation of cancer immunotherapy", 58th Annual Meeting of The Italian Cancer Society. Revolutionary Road: Accelerating Conversion of Cancer Biology into Personalized Clinical Oncology, September 5-8, 2016, Verona, Italy.
140. **V. Bronte.** "Immune suppressive and immune stimulating monocytes in cancer", Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Meeting, September 25-28, 2016, New York, USA.
141. **V. Bronte.** "Myeloid Derived Suppressor Cells", Metchnikoff's Legacy: Tissue Phagocytes and Functions - EFIS-EJI Ruggero Ceppellini Advanced School of Immunology, October 12-14, 2016, Naples, Italy.
142. **V. Bronte.** "Altered Myelopoiesis and Immune Dysfunctions During Cancer Progression", Easton Seminar, Immunology Department, University of Toronto, October 24, 2016, Toronto, Canada.
143. **V. Bronte.** "Molecular and metabolic control of adaptive immunity in cancer", Viruses, Inflammation and Cancer, November 14-16, 2016, Venice, Italy.
144. **V. Bronte.** "Boosting cancer immunotherapy by interfering with myeloid-dependent suppression", eati.lectures, European Academy of Tumor Immunology, December 5, 2016, Paris, France.
145. **V. Bronte.** "Myeloid-derived suppressor cells and their contribution to tumor immune escape", 2nd Symposium on Advances in Cancer Immunology and Immunotherapy, December 15-17, 2016, Athens, Greece.
146. **V. Bronte.** "Apoptosis Regulation and Immune Suppressive Programs in Tumor-Conditioned Monocytes", 9th Cellular Therapy Symposium, March 16-17, 2017, Erlangen, Germany.
147. **V. Bronte.** "Role of Myeloid-Derived Suppressor Cells in Tumor Immunity", Keystone Symposia, Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology, March 19-23, 2017, Whistler, Canada.
148. **V. Bronte.** Chairman in "Phagocytes in tumor biology and immunotherapy" Session, ESCI Conference 2017, 51st Annual Scientific Meeting of the European Society for Clinical Investigation, May 17-19, 2017, Genoa, Italy.
149. **V. Bronte.** "Immuno regulatory pathways in tumor-conditioned monocytes", Istituto Italiano di Cultura, May 24-26, 2017, Prague, Czech Republic.
150. **V. Bronte.** "Manipulating the Tumor Environment", FOCIS - SITC Course on Cancer Immunity and Immunotherapy, June 14, 2017, Chicago, Illinois.
151. **V. Bronte.** "Immune regulatory programs and apoptosis in myeloid-derived suppressor

cells", 14th International Conference on Innate Immunity, June 19-24, 2017, Heraklion, Crete .

152. **V. Bronte.** Third annual CRI-CIMT-EATI-AACR international cancer immunotherapy conference, September 6-9, 2017, Mainz/Frankfurt, Germany.
153. **V. Bronte.** "Myeloid cells assist tumor progression by molecular mechanisms either dependent or independent from adaptive immunity", 17th International Conference on Progress in Vaccination Against Cancer, September 27-30, 2017, Loutraki, Corinth, Greece.
154. **V. Bronte.** "Myeloid regulatory cell biology", Final COST AFACTT meeting Cell-based Tolerance inducing therapies, October 11-13, 2017, Barcelona, Spain.
155. **V. Bronte.** "Tumour Immunology: from tissue microenvironment to immunotherapy", Ruggero Ceppellini Avanded School of Immunology, October 16-18, 2017, Naples, Italy.
156. **V. Bronte.** "Monocytes and Macrophages in Cancer", SITC 32nd Annual Meeting, November 8-12, 2017, National Harbor, Maryland.
157. **V. Bronte.** "Role of myeloid-derived suppressor cells in cancer immune evasion", 23rd Congress of EHA, November 24, 2017, Amsterdam.
158. **V. Bronte.** "Alteration of monocyte survival and immune dysfunctions in cancer", Cancer immunotherapy 2017, November 28, 2017, Paris, France.
159. **V. Bronte.** "Myelopoiesis and cancer: "Flipping" over monocytes into immune suppressive cells" + Q&A session" INGM, February 13, 2018, Milano, Italy.
160. **V. Bronte.** "Arginase Inhibitors" TAT 2018, March 5-7, 2018, Paris, France.
161. **V. Bronte.** "Myelopoiesis and cancer: "Flipping" over monocytes into immune suppressive cells" CIMT 2018, May 15-17, 2018, Mainz, Germany.
162. **V. Bronte.** "Macrophages assist metastatic process through the regulation of endocytic pathway" 15th Int'l Conference on Innate Immunity, June 18-23, 2018, Crete, Greece.
163. **V.Bronte.** "Flipping" over monocytes into immune regulatory cells" ECI Congress 2018, September 2-5, 2018, Amsterdam, Netherlands.
164. **V. Bronte.** "Altered myelopoiesis in cancer" ImmunoRad, September 20-22, 2018, Parigi, France.
165. **V. Bronte.** "Myelopoiesis in cancer: "Flipping" over monocytes into immune regulatory cells" XVI NIBIT meeting, October 11-13 2018, Milan, Italy
166. **V. Bronte.** "Lesson from Cancer: "Flipping" over Monocytes into Immune-suppressive Cells" XII annual Ri.MED scientific symposium, October 12, Palermo, Italy.

PATENTS

- 1) Borrello IM, Serafini P, Noonan KA, Bronte V. (2006). **PDE5 Inhibitor compositions and methods for immunotherapy.** The Johns Hopkins University. PCT/US06/00699.
- 2) Bronte V, Viola A, Gasco A, Fruttero R, Crosetti M. (2011). **New idrosoluble furoxan derivatives having antitumoral activity.** Humanitas Mirasole spa, Istituto Oncologico Veneto IRCCS. PCT/IB2011/050743.
- 3) Bronte V, Viola A, Gasco A, Fruttero R, Crosetti M. (2009). **Nitric oxide furoxan derivative compounds endowed with antitumoral activity.** Humanitas Mirasole Spa, Istituto Oncologico Veneto IRCCS. PCT/EP2009/000206.

- 4) Bronte V, Mandruzzato S. (2009). **Myeloid-derived suppressor cells generated in vitro.** Istituto Oncologico Veneto IRCCS. PCT/IB2009700137.
- 5) Singh H, Mendrzyk R, Walter S, Bronte V, Mandruzzato S. (2010). **Use of myeloid cell biomarkers for the diagnosis of cancer.** Immatics Biotechnologies GmbH. 2912919-026000.
- 6) Ugel S, Sandri S, Bobisse S, Bronte V. (2015), Sequenza genica codificante un Tcr specifico per il complesso MHC di classe I umano specifico per il complesso HLA-A02 ed il peptide htert865-873, nonché e il suo impiego per ingegnerizzare linfociti T per possibili applicazioni cliniche di trasferimento adottivo. **Gene sequence encoding a mouse TCR specific for the human HLA-A2 complex and hTERT865-873 peptide and its use for engineering human T lymphocytes for adoptive cell therapy of cancer.** Partner: University of Verona. PCT/IB2016/051510.
- 7) Bronte V, Ugel S, Fiore A, Sahin U. (2017). **ENGINEERED CELLS FOR INDUCING TOLERANCE.** Partner: BioNTECH AG. 674-208 PCT.
- 8) Serafini P, Bronte V. (2017). **Nanoparticle conjugates and uses thereof.** Partner: University of Miami, Florida, USA. PCT/EP2017/1453.

MEMBERSHIP

Member of the American Association for Cancer Research (AACR).
Member of the American Association of Immunologists (AAI).
Member of the Società Italiana di Immunologia, Immunologia Clinica ed Allergologia (SIICA).
Member of Network Italiano per la BioTerapia dei Tumori (NIBIT).
Member of the Accademia Nazionale di Medicina (ANM).
Member of Società Italiana di Cancerologia (SIC).

TEACHING

Since 1989 Dr. Bronte has been teaching Immunology, Immunohaematology, Immunopathology, Molecular and General Pathology as non-tenured Professor of the Medicine Faculty, University of Padova. From January 2011, he is full professor of Immunology and Immunopathology at Verona University.

REFEREE

Ad hoc reviewer for: Science, Nature Medicine, Nature Immunology, Nature Genetics, Nature Reviews Immunology, Immunity, Cancer cell, Nature Communications, Journal of Experimental Medicine, Journal of Clinical Investigation, Cancer Discovery, Journal of Immunology, Gastroenterology, Cell Reports, Blood, Proceedings of the National Academy of Sciences, American Journal of Pathology, Cancer Research, Cancer Immunology Research, Journal of Immunotherapy, European Journal of Immunology, International Journal of Cancer,

Journal of Translational Medicine, Human Gene Therapy, Vaccine, Cellular Immunology, Immunology Letters, Clinical Immunology, Cancer Letters, Cancer Immunology Immunotherapy, Journal of Leukocyte Biology, FEBS letters, Oncoimmunology, Oncotargets.

COMMISSIONS OF TRUST

Peer Reviewer for European Research Council (ERC) Grant Applications.
Peer Reviewer for National Institutes of Health (NIH) Grant Applications, US.
Peer Reviewer for Evaluation process of Laboratories of excellence ANR (French Research Funding Agency), France.
AIRC fellowship reviewer, Member of Advisor Scientific Board, Italy.
Peer Reviewer for National Medical Research Council (NMRC) Grant Application, Singapore.
Review panel member, Danish Council for Independent Research, Ministry of Higher Education and Science, Denmark.
Peer Reviewer for WorldWide Cancer Research Grants, UK.
Peer Reviewer for Stichting tegen Kanker / Fondation contre le Cancer Grant, Belgium.
Visiting committee to assess the research activity of the unit "Tumor immunology and immunotherapy of cancer, Institut Gustave Roussy, Aeres, France.
Peer Reviewer for Cancer Research UK Grant Applications, UK.
Peer Reviewer for "SIR 2014" of MIUR Italy.
Expert reviewer for MATWIN Programme.
Member of Review Committee Breast Cancer Now's Research Unit at Kings College London February 8, 2018.
Peer Reviewer for Independent Research Fund Denmark | Medical Sciences Grant Applications.
Peer reviewer for Swedish Research Council Grant Applications.
Peer reviewer for Université Bourgogne Franche-Comté Grant Applications (UBFC)

COLLABORATION WITH COMPANIES

ITeos Therapeutics SA, scientific advisory board and research collaboration
Tusk Therapeutics Ltd, scientific advisory board, research support and collaboration
IO Biotech ApS, shareholder and scientific advisory board
BioNTech AG, patent and research collaboration
Ganymed Pharmaceuticals AG, research collaboration
Xios Therapeutics, scientific advisory board
Codiak BioSciences, scientific advisory board
Calithera Bioscience Inc., past research collaboration
Roche Ltd, past consultancy and research collaboration

Autorizzo il trattamento dei miei dati personali ai sensi dell'art. 13 d. lgs. 30 giugno 2003 n°196 – "Codice in materia di protezione dei dati personali" e dell'art. 13 GDPR 679/16 – "Regolamento europeo sulla protezione dei dati personali".

Verona 12.11.2018

Firma



